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ABSTRACT OF DISSERTATION

ELUCIDATING MOLECULAR FUNCTION OF MITHRAMYCIN AND
ANALOGUES FOR THE TREATMENT OF EWS-ETS EXPRESSING
CANCERS
Introduction: Chromosomal translocations are common in cancer. In many cancers
such as prostate cancer, leukemia and Ewing sarcoma, chromosomal translocations are the
main driver of malignancy. Ewing sarcoma is a cancer diagnosed mostly in children and
adolescents that has very grim outcomes for patients with metastasis and recurrent disease.
Malignancy in Ewing sarcoma is due to EWS-FLI1, an aberrant transcription factor that is
the result of a chromosomal translocation. EWS-FLI1 is the main driver of oncogenesis in
Ewing sarcoma and has been the target of many drugs developed to treat the disease.
Mithramycin (MTM) was identified as a potent inhibitor of EWS-FLI1, but despite its preclinical success there were serious toxicities associated with its use including
hepatotoxicity. Adverse effects associated with MTM treatment resulted in treatment
regimens that were not enough to decrease tumor size. Because of dose limiting toxicities
there has been a collective effort to develop analogues of MTM that are less toxic but more
effective against inhibiting EWS-FLI1 activity. Here I present an assessment of the unique
molecular biologic activity of novel MTM analogues.
Preliminary pharmacokinetic studies have shown that in mice MTM has a shorter
plasma half-life of about five hours [1]. MTM analogues MTMSA-TRP and MTMSATRP-TRP have extended plasma half-lives of twelve hours and over eighteen hours,
respectively. Due to their longer plasma half-lives we hypothesized that MTM analogues
have less affinity for organic anion transporting polypeptides (OATP) because of their
physiochemical properties.
Additionally, DNA binding assays suggested that MTM analogues bind DNA and
stabilize the EWS-FLI1 transcription factor reducing transcription of EWS-FLI1 target
genes [2]. We hypothesize that MTM analogues bind DNA displacing and/or stabilizing
EWS-ETS transcription factors. These analogues bind DNA resulting in DNA damage, we
hypothesize that combining MTM analogues that cause DNA damage with PARP1
inhibitors will result in a synergistic response in cell lines expressing EWS-FLI1.
Methods: Based on preliminary cytotoxicity and pharmacokinetic studies, the
ionization constant (pKa) of MTM and analogues was measured. Based on the fluorescence

of MTM core aromatic rings at increasing pH, pKa values were estimated. RKO cells stably
transfected with pIRES/OATP1B1 or pIRES/OATP1B3 expression vectors were used to
complete competitive inhibition studies. Measuring MTM and analogue competition into
OATP vs. 8- (2- [fluoresceinyl]aminoethylthio) adenosine- 3', 5'- cyclic monophosphate
(8-FcA), a fluorescent substrate of OATP transporters. OATP expressing cells were also
subjected to cytotoxicity studies to evaluate uptake of MTM analogues over a 72-hour
assay. FVB/N Oatp1a/1b knockout (KO) and FVB/N wildtype mice were used to complete
pharmacokinetic studies evaluating differences in uptake of MTM and MTMSA-TRP-TRP
after pre-treatment with the OATP inhibitor rifampicin for 1 hour.
Time-resolved fluorescent energy transfer (TR-FRET) assays used CAL635
labeled DNA oligomers specific for ERG-his tagged and Sp1-his tagged peptides.
Europium-labeled (EU) anti-HIS antibodies were combined with the peptide to evaluate
shifts in FRET, a response to treatment with MTM or analogue. Cellular thermal shift
assays (CETSA) were used to determine shifts in thermal stability of EWS-FLI1, Sp1 and
RNA polymerase II (RNAPII). Protein expression studies evaluating expression of MTM
analogue activity against RNAPII phosphorylated Serine 2 (p-Ser2) on its c-terminal
domain (CTD). mRNA expression of DNA damage repair genes CDK12, BRCA1, FANC1
and FANCD2 in cell lines expressing EWS-FLI1 (TC-32 and A673) vs. cell lines that do
not express EWS-FLI1 (PC3 and TC-32shEWS-FLI1#6) was also evaluated. Protein
expression of the dsDNA damage biomarker γ-H2AX was also evaluated in TC-32 and
PC3 cell lines. TC-32 and PC3 cells were also used to evaluate synergy between MTM
analogues and the PARP1 inhibitor olaparib. Results from cytotoxicity studies were used
to calculate the combination index (CI) values of each drug combination. Based on CI
values from in vitro studies a xenograft study in female athymic nu/nu mice evaluating
tumor regression after treatment with olaparib and MTMSA-TRP was conducted.
Results: Evaluation of the molecular function of MTM analogues was largely based
on differences in their structure and pKa. pKa estimation studies revealed that analogues
with large hydrophobic conjugations to the C3 side chain of MTM, resulted in a higher pKa
than the parent compound MTM. This result also correlated with OATP mediated uptake
into RKO-OATP1B1 and RKO-OATP1B3 cells in competition assays and in cell viability
assays. Pharmacokinetic studies in OATP1B1 humanized mice demonstrated an increase
in exposure of MTM after treatment with rifampicin.
TR-FRET and CETSA assays demonstrated pointed evidence of displacement and
stabilization of EWS-FLI1 and ERG transcription factor DNA binding domains (DBD). In
TR-FRET assays MTM analogues with amino acid side chains displaced ERG binding
more potently than they did SP1, and CETSA assays demonstrated a physical interaction
between EWS-FLI1 and MTM analogues. Sp1 CETSA experiments showed minimal shifts
in thermal stability between the different analogues, suggesting that there is no physical
interaction between analogue and the Sp1 transcription factor. RNAPII CETSA
experiments showed that MTM and MTMSA analogues were more likely to stabilize this
protein vs. MTMox analogues. Protein expression of RNAPII CTD p-Ser2 also
demonstrated a concentration and EWS-FLI1 dependent decrease in expression. mRNA
expression of DNA damage repair proteins CDK12, BRCA1, FANC1 and FANCD2 was
assessed by qRT-PCR, indicating that MTM and analogues also induce a decrease in their
expression in an EWS-FLI1 and concentration dependent manner. These interactions were
the rationale to investigate the possibility of MTM analogues being DNA damaging agents

and transcriptional inhibitors. MTM analogues were shown to induce DNA damage in TC32 cells but not in PC3 cells, demonstrating a concentration and EWS-FLI1 dependent
increase in γH2AX expression. Cell viability studies combining MTM, analogues and
olaparib proved synergy specific to cells expressing EWS-FLI1. Xenograft synergy studies
also showed that we can lower the dose of MTMSA-TRP combined with olaparib and gain
a more sustained reduction in tumor size.
Conclusion: These studies in whole highlight the importance of developing and
understanding the underlying mechanism of these novel analogues. Physiochemical
properties of the analogues compared to MTM directly contribute to their exposure. And
binding properties correlate with specificity and cytotoxicity in ETS translocation
expressing cell lines. MTMSA-TRP has also shown promise in xenograft studies however,
in these studies we combined it with olaparib to take advantage of the synthetic lethality
imparted on cell lines that express EWS-FLI1.
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CHAPTER 1. INTRODUCTION
Malignancies associated with chromosomal translocations
Cancer is the result of aberrant genetic changes gone unchecked and uncorrected
in a cell. The cell divides, and the consequence is a malignant tumor that grows and
causes numerous health issues. Many cancers arise from genetic aberrations known as
chromosomal translocations [3-5]. Chromosomal translocations have a significant role in
the initiation of carcinogenesis by forming gene fusions that are responsible for
approximately 20% of human cancers [6, 7]. Chromosomal translocations describe
chromosomal rearrangements involving the interchange of parts between two nonhomologous chromosomes and are generally classified as reciprocal and non-reciprocal
translocations. Reciprocal translocations occur as the exchange of broken DNA segments
while non-reciprocal translocations occur when two chromosomes fuse near the
centromeric region. Common consequences of chromosomal translocations are the
juxtaposition of the coding region of a gene close to the transcriptionally active promoter
region of another gene or the translocation can result in the formation of a chimeric
fusion gene [3].
Chromosomal translocation leading to juxtaposition and overexpression
1.1.1.1 Burkitt’s lymphoma
A highly aggressive B cell non-Hodgkin lymphoma, Burkitt’s lymphoma
(BL) is characterized by the t(8;14)(q24;q32) translocation [3, 8, 9]. Development of BL
is dependent on overexpression of the MYC gene, which encodes for the c-myc protein
transcription factor and is regulates cell proliferation, differentiation, and apoptosis.
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Overexpression of c-myc is due to a chromosomal translocation resulting in the
juxtaposition of the c-MYC gene, located on 8q24, to the Ig heavy chain gene on
chromosome 14, bringing the gene under the regulation of the IgH enhancer. All these
factors contribute to cellular transformation in BL [10, 11].
1.1.1.2 Prostate cancer
Prostate carcinoma is one of the most common cancers in men worldwide.
Malignant transformation of the prostate has been shown to be due to many different
factors, but ~50% of localized prostate cancers are the result of chromosomal
translocations [12, 13]. A recurrent gene fusion of the 5’ untranslated region of
TMPRSS2 to ERG (TMPRSS2:ERG) was the first to be discovered [14]. Other recurrent
gene fusions have also been found between TMPRSS2 and ETV1, ETV4 and ETV5 [15].
Notably, TMPRSS2-ETV1 fusion is the result of a chromosomal translocation while
TMPRSS2-ERG is due to the deletion of ETS2 resulting in expression of truncated human
ERG [16, 17].

Chromosomal translocations leading to a chimeric gene
1.1.2.1 Breast cancer
Breast cancer is one of the most common cancers diagnosed in women
worldwide. Secretory breast carcinoma, a rare subset of breast cancer, was shown to
express a translocation between ETV6 and NTRK3, t(12;15) [18]. The translocation
produces the fusion gene, ETV6-NTRK3 [19]. This gene is then translated into a chimeric
protein consisting of the protein tyrosine kinase domain of NTRK3 and the
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oligomerization domain of ETV6. This chimeric protein causes malignant transformation
of cells through activation of the MAP Kinase and the PI3 Kinase/AKT pathways [20].
1.1.2.2 Acute myeloid leukemia
Acute myeloid leukemia (AML) is a progressive malignant disease in
where there are too many immature blood‐forming cells accumulating in the bone
marrow and interfering with the production of normal blood cells [21]. The identification
of recurrent chromosomal translocations in AML has been thoroughly studied and
characterized. Common chromosomal translocations in AML include t(15;17) [22] ,
t(8;21), inv [23] and 11q23/MLL, these abnormalities are seen in 3-10% of AML cases.
These chromosomal translocations encode specific oncofusion proteins PML-RARA,
AML1-ETO, CBFB-MYH11 and MLL fusions respectively [21].

1.1.2.3 Ewing Sarcoma
Ewing’s sarcoma (ES) is the second most common bone malignancy
diagnosed in children and adolescents [24]. It is most common in Caucasian males aged
10-19 years of age. Most ES cases arise in the bone and up to 30% in soft tissue [25]. At
the molecular level, ES is characterized by the identification of chromosomal
translocations between genes in the EWS family and genes in the ETS family. The
majority (99%) of ES cases involve genes from these two families. Among them, 85% of
patients diagnosed with ES have an t(11;22) chromosomal translocation. This produces
the EWS-FLI1 fusion gene which is then translated into the EWS-FLI1 fusion
transcription factor [24].
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Molecular genetics of Ewing sarcoma
Ewing sarcoma is in 85% of cases associated with the chromosomal
translocation t(11;22)(q24;q12), which leads to the formation of the EWS-FLI1 fusion
gene (Figure 2) [24, 26]. In the other 10-15% of cases the translocation t(21;12)(22;12)
leads to the formation of the EWS-ERG fusion gene, the remaining 1-5% of cases contain
one of several possible translocations. All Ewing sarcoma cases harbor a fusion gene
containing a portion of the EWS gene and a member of the ETS family of transcription
factors (Table 1.1).
Table 1.1. Summary of the different fusions between non-ETS and ETS genes and their
frequency in Ewing sarcoma tumors.
Non-ETS
EWS
EWS
EWS
EWS
EWS
TLS

ETS
FLI1
ERG
ETV1
ETV4
FEV
ERG

Frequency (%)
85
10
<1
<1
<1
<1

EWS role in cancer
EWS is related to TLS/FUS, a gene that has been shown to be fused to the
CHOP transcription factor via chromosomal translocation in myxoid liposarcoma [27].
EWS, TLS/FUS and TAFII68, a TBP associated factor, together form the TET family of
proteins. These genes are characterized by an 87 amino acid RRM/RNP-CS domain that
has been implicated in protein-RNA binding [28]. TET proteins have been shown to
harbor a variable number of RGG (arginine-glycine-glycine) repeats that promote RNA
binding. They also possess a glutamine rich N-terminal region that becomes fused to
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ETS genes in Ewing sarcoma and they also affect a variety of genes encoding
transcription factors in many other cancers [29].
TET proteins have been shown to interact with splicing proteins,
participate in transcription and RNA processing, more specifically in in vitro studies
EWS has been shown to form complexes with TFIID, RNA polymerase II (RNAPII) and
the coactivators CBP/p300 [30-32]. TET family members have been shown to be
essential in B lymphocyte development and with TLS/FUS knockdown there is marked
chromosomal instability [33].
ETS role in cancer
The avian leukemia virus E26 (ETS) was identified by Leprince et al in
1983, setting the stage for identification and characterization of a protein family of over
30 members [34]. This large family of proteins is characterized by the presence of an 85
amino acid sequence, the ETS domain (Figure 1). The ETS domain consists of a
conserved winged helix-turn-helix DNA binding domain at the C-terminus [35]. ETS
proteins have been shown to associate with chromatin and have DNA binding activity
that is highly dependent on the integrity of the ETS domain [36, 37]. Specifically, the
ETS DNA binding domain recognizes sequences containing GGAA/T [38]. The ETS
family of transcriptions factors control genes that play critical roles many cellular
processes including cell proliferation, apoptosis, differentiation, lymphoid cell
development, angiogenesis, and invasiveness [35].
ETS genes involvement in cancer has been heavily studied since it was
first demonstrated by the presence of the oncogenic virus E26. The importance of ETS
genes in cancer development supported by the observation of human ETS genes located
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at translocation breakpoints [39-42]. The most notable translocation being EWS-FLI1,
where the FLI1 gene is translocated developing a fusion gene with the EWS locus [24].
This translocation forms a chimeric protein that regulates ectopic target genes.
Additionally, other ETS factors are also overexpressed and/or down regulated in cancers.
In some breast cancers and prostate cancers ETS-2 is overexpressed, which was later
found to be necessary for transformation in these cancers [42].
Mechanism of action of EWS-ETS fusion proteins
Studies have shown that EWS-FLI1 along with other EWS-ETS fusion
proteins function as aberrant transcription factors. This is demonstrated by observations
that EWS-ETS proteins localize in the nucleus, bind DNA in a site specific manner and
possess an EWS domain that acts as a powerful transcriptional activator that is markedly
more potent than that of native FLI1 domain displaced as a result of the chromosomal
translocation [24]. Notably, ETS family members that form fusion proteins with EWS,
such as FLI1, ERG and ETV1were found to also bind with Fos-Jun whereas other ETS
family members were not [43]. Suggesting that cooperation between EWS-FLI1 and FosJun is essential for at least some of its biological activities. EWS-FLI1 also associates
with RNA helicase A (RHA), subsequent studies identified RHA in a protein complex
with EWS-FLI1 binding to known EWS-FLI1 target gene promoters thereby enhancing
EWS-FLI1 function [44].
Identifying putative target genes of EWS-FLI1 has also been essential to
understanding its mechanism of action. Using subtractive hybridization three genes that
were found to be induced by EWS-FLI1 but not by FLI1 alone were identified: EAT-2
(an SH-2 domain containing protein), mE2-C (a cyclin-selective ubiquitin ligase) and
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MFNG (manic fringe gene encoding a glycosyltransferase involved in somatic cell
development) [45-47]. There have also been efforts to identify EWS-FLI1 targets that
have implications on targeted therapy including: NROB1, GLI1, FOX transcription
factors, CCK and LOX [48].

Treatment of Ewing sarcoma
Standard of care and prognosis
Initially, Ewing sarcoma was treated with surgery and radiation alone, this
treatment was unsuccessful and resulted in in a high fatality rate. However, in the past 40
years the prognosis for patients with Ewing sarcoma has greatly improved [49]. This
improvement arises from the addition of systemic therapy in the form of chemotherapy.
Major areas of concern, however, continue to be patients that arrive in the clinic with
recurrent and/or metastatic disease. In patients with localized disease the administration
of multimodality treatments has resulted remarkable improvement but, the outcome of
patients with metastatic or recurrent disease remains dismal [50]. Currently, for nonmetastatic Ewing sarcoma in the US treatment includes vincristine, doxorubicin and
cyclophosphamide (VDC) with courses of ifosfamide and etoposide (IE) every 3 weeks
for 48 weeks with local control at 9-12 weeks [51].
Ewing sarcoma has the potential for metastasis and the most common
sites of metastasis include lung, bones, and bone marrow. In 25-30% of Ewing sarcoma
patients present with metastatic disease, these patients have a low survival rate [52]. The
chemotherapy regimen and initial treatment for patients with metastatic disease is the
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same as that for localized disease. If tumor progression continues there is little hope for
cure in these patients.

Trabectedin reverses the transcriptional signature of EWS-FLI1
Trabectedin is a natural product that was originally isolated form the sea squirt
Ecteinascidia turbinate [53]. Trabectedin binds DNA in the minor groove at GC-rich
sequences and alkylates the amino group of guanine at position 2, bending DNA toward
the major groove (

Figure1.1) [54]. A potent alkylator, its cytotoxicity comes from its ability to
interact with DNA repair pathways. Trabectedin-DNA adducts can trap the transcriptioncoupled DNA nucleotide excision repair (TC-NER) system as it repairs DNA damage in
transcribing cells, this then leads to lethal DNA breaks [55].
Clinically, trabectedin has shown activity in a wide range of malignancies.
Most notably in leiomyosarcoma and liposarcoma [56]. Previously it has been shown
that sarcomas harboring chromosomal translocations are sensitive to trabectedin
treatment [57]. Taamma et.al reported a 50% response rate in patients with myxoid
liposarcoma which harbors a (12:16) chromosomal translocation (FUS-CHOP) after
treatment with trabectedin [57]. This finding has identified trabectedin as a potential drug
of interest for the treatment of ES. Preclinical studies have shown that ES cells are
sensitive to trabectedin treatment and there is mechanistic evidence that trabectedin
interferes with EWS-FLI1 activity in vitro, reversing the gene signature of the aberrant
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transcription factor [58-60]. Trabectedin has not shown success in the clinic in ES
patients but there have been efforts to develop analogues that can better target the EWSFLI1 translocation [61]. Lurbinectedin, a trabectedin analogue has shown evidence of
activity against EWS-FLI1. This second generation trabectedin analogue causes nuclear
redistribution of EWS-FLI1 from the nucleus to the nucleolus, similar to that of the
parent compound trabectedin [62]. Lurbinectedin is currently being tested in a phase 2
clinical trial in select advanced solid tumors [63].

Figure1.1. Trabectedin binding alkylates DNA distorting its structure and inhibits DNA
repair protein activity and transcription factor activity.

Inhibition of transcriptional regulators
1.3.3.1 LSD1
Although there have been multiple efforts to target the transcription factor EWSFLI1, the main oncogenic driver in ES, there has been little success in identifying a
potent yet clinically acceptable small molecule inhibitor of the transcription factor. ES
9

has one of the lowest mutation rates of any cancer and it has emerged as a model system
to investigate epigenetic aberrations resulting in oncogenesis [64-66]. Lysine specific
demethylase 1 (LSD1) is an enzyme that functions as a histone demethylase and as a
transcriptional activator and repressor [67]. LSD1 has been implicated in many
malignancies including breast, prostate, bladder, lung, liver, neuroblastoma, amyloid
leukemia and colorectal tumors [68-73]. In 2011 it was reported that ES expresses
unusually high levels of LSD1 [74, 75]. It has also been demonstrated that
overexpression of LSD1 can drive transformation in cells [70, 75, 76]. Previous studies
have demonstrated that LSD1 is required for chromosome segregation and
downregulation of LSD1 can lead to abnormal centrosome duplication. This significantly
impairs nuclear pore complex assembly, leading to an extended telophase [77, 78].
Initially LSD1 inhibition in ES was tested using tranylcypromine [74].
Tranylcypromine is currently prescribed as an anxiolytic and antidepressant. However,
because of severe side effects associated with its treatment, its use is limited to treating
patients with major depressive disorders [79]. It was shown that tranylcypromine inhibits
LSD1 in a non-reversible manner, which translated to decreased cell proliferation at
millimolar concentrations in ES cells, thus supporting further exploration and
development of a more potent and specific LSD1 inhibitor (Figure 1.2) [74]. Sankar et al
have been investigating the therapeutic potential of HCI-2509, a non-competitive
reversible small molecule inhibitor of LSD1, for the treatment of ES [80]. Their studies
demonstrated that HCI-2509 can reverse the global oncogenic transcriptional program in
ES with the use of cell viability assays and RNA-sequencing [80]. They also
demonstrated that HCI-2509 impairs tumorigenesis in vivo. As a single agent HCI-2509
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decreased tumor size in comparison to the vehicle group, which led to improved survival
of treated animals over 60 days, but these differences were not statistically significant
[80]. Despite this limited efficacy, an analogue of HCI-2509 known as SP-2577 is
undergoing phase 1 clinical testing [81].

Figure 1.2. LSD1 inhibitors bind LSD1 and prevent its interaction with EWS-FLI1.

1.3.3.2 Kinase Inhibitors
One approach to treating ESFT is to target the basic transcriptional machinery
with small molecule inhibitors such as THZ1, which is a covalent inhibitor of
CDK7/12/13 [82]. The control of gene transcription involves a set of cyclin-dependent
kinases (CDKs), including CDK7, CDK8, CDK9, CDK11, CDK12, CDK13, and CDK19
these kinases are essential to transcription, initiation, and elongation. Specifically, CDKs
phosphorylate RNA polymerase II (RNAPII) at its C-terminal domain (CTD) causing
recruitment of transcriptional activators to the transcriptional complex [83]. THZ1 was
implicated as a potential therapeutic for treating cancers defined by their high
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dependency on transcriptional programs for initiating transformation [84]. This was
further demonstrated when 1,081 cancer cell lines were screened, and ES cell lines were
shown to be the most sensitive to THZ1 treatment [85]. Iniguez et al reported that in ES
cell lines THZ1 primarily targets CDK12 (
Figure 1.3), a kinase that regulates expression of DNA damage repair genes [85,
86]. Because of non-specific targeting the THZ1 analogue THZ1531 was developed and
tested in preclinical studies. These studies showed that THZ1531 was highly active in
cells expressing EWS-FLI1, specifically showing an increase in proteins involved in
double stranded DNA damage repair. Considering this discovery, they then hypothesized
that cells expressing EWS-FLI1 are more vulnerable to THZ1531 and other DNA
damage repair inhibitors. ES cell lines have been reported to be highly sensitive to
PARP1 inhibitors [87]. Pre-clinical combination study results showed strong synergy
with THZ1531 and the PARP1 inhibitor olaparib.
Xenograft studies using THZ1 as a single agent did not cure mice of ES,
suggesting that the combination of THZ1 and olaparib could be necessary to achieve
complete efficacy [85].

Treatment of tumors with the combination of THZ1 and

olaparib demonstrated a marked decrease in tumor size compared to control groups [85].
The ES genome is characterized by one of the lowest mutational rates amongst
cancer types, implicating a possibility for epigenetic deregulation as a component for
tumor development [65, 66, 88]. Reports have shown that about 13 to 30% of ES tumors
possess deletions in the gene CDKN2A, although these deletions do not appear to be
associated with clinical outcome there is still some implication that this could be a target
for pharmacological drug development [72, 89]. In ES, the tumor suppressors p16INK4a
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and p14arf arise from variant transcription start points of the CDKN2A gene. and p16 has
been shown to inhibit CDK4 and CDK6 (Figure 1.4) mediated phosphorylation of the RB
protein, preventing cell cycle progression [90]. The alteration of p16INK4a in ES has
sparked clinical interest in CDK4/6 inhibition. Cyclin D1, a regulatory subunit of CDK4
and CDK6, has also been shown to be a super enhancer in ES [91] and consequently, in
ES cells, the CyclinD1/CDK4 pathway is activated and is required for growth. Kennedy
et al conducted xenograft studies where they demonstrated that CDK4/6 inhibition
decreased tumor growth [91]. These results suggest yet another potential pathway to
target oncogenic drivers of ES at the molecular level.
Currently, the CDK4/6 inhibitor, abemaciclib is being evaluated in a Phase I
clinical trial in children and adults with recurrent and refractory ES, neuroblastoma,
rhabdomyosarcoma and osteosarcoma [92]. The main toxicity associated with CDK4/6
inhibition is hematologic in nature and there is growing interest in combining CDK4/6
inhibitors with cytotoxic chemotherapeutics that have non-overlapping toxicities [93].
There is also interest in combining CDK4/6 inhibitors with MEK, mTOR and IGF-1R
inhibitors, exploiting multiple pathways focusing on targets that can influence tumor
growth in ES [94-96].
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Figure 1.3. CDK12 inhibitors bind cyclin/CDK complexes preventing phosphorylation.

Figure 1.4. CDK4/6 inhibitors bind cyclin/CDK complexes preventing phosphorylation.

1.3.3.3 Microtubule inhibitors
Microtubules help support organelles, transport molecules, and give shape to the
cell. The microtubule inhibitor eribulin inhibits polymerization of tubulin subunits by
preventing lengthening and shortening of microtubules during cellular division (Figure
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1.5) [95, 97]. When these unstable polymers of tubulin aggregate the result is apoptosis
[98, 99]. Eribulin is approved by the FDA for treating metastatic breast cancer and may
have promising activity in other cancers [100]. In ES, EWS-FLI1 drives expression of
proteins that regulate microtubule stability, making this an attractive drug target. In preclinical studies, testing of Eribulin in ES cell lines demonstrated Bcl-2 induced apoptosis
[101]. Additionally, eribulin is FDA-approved for adult patients with liposarcoma who
previously received an anthracycline [102]. An ongoing phase 2 trial is evaluating
eribulin in patients with relapsed/refractory rhabdomyosarcoma and ES [103]. Another
phase 1/2 clinical trial is evaluating the combination of eribulin with irinotecan in
children with refractory and recurrent rhabdomyosarcoma and ES as well [104]. Overall,
eribulin has shown strong pre-clinical and clinical results in ES, thus giving it great
potential as either a monotherapy or in combination with another approved
chemotherapeutic.

Figure 1.5. Eribulin inhibits microtubule growth causing nonproductive tubulin aggregates.
1.3.3.4 PARP1 inhibitors
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Mechanistically, poly adenosine diphosphate ribose polymerase (PARP1)
is an enzyme that has been shown to both drive transcription and to accelerate base
excision repair [105-107]. Initial interest in PARP11 inhibitors have shown promising
activity particularly in BRCA-mutant cancers defective in homologous repair (HR), in
which they have demonstrated replication fork stalling and subsequent synthetic lethal
cell death [108-110]. PARP1 inhibitors have also recently been of interest for the
treatment of ES (Figure 1.6). It has been reported that ES cells express high levels of
PARP1 mRNA and protein and which translates to high PARP1 activity related to an
increase in copy number compared to other cancers [111]. Increased PARP1 activity led
to the report that inhibition of PARP1 sensitized ES cells to ionizing radiation [111]. In
more recent studies Brenner et al showed increased sensitivity of three ES cell lines to
the PARP1 inhibitor olaparib, as opposed to an osteosarcoma and rhabdomyosarcoma
cell line [112]. In this study however, olaparib was not effective as a single agent in
xenograft experiments. They subsequently combined olaparib with temozolomide, a
DNA alkylating agent, results displayed a marked decrease in tumor size of the xenograft
models. These data represent the potential for elucidating synthetic lethality in ES cells
in the presence of a PARP1 inhibitor and a DNA damaging agent [112]. In 2014 a phase
II clinical study was conducted evaluating the antitumor activity of olaparib, as a
monotherapy in patients with refractory ES following failure of standard chemotherapy
[113]. This study concluded that olaparib administration was safe and well tolerated in
patients. However, as a monotherapy there were no significant responses or durable
disease control [113]. Currently a phase I study of olaparib and temozolomide for the
treatment of ES is ongoing [114] .
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Figure 1.6. PARP1 binds DNA and repairs DNA breaks, in the presence of olaparib PARP1
activity is inhibited rendering the cell vulnerable to consequences of DNA damage.

Targeting of EWS-FLI1
1.3.4.1 YK-4-279
The EWS-FLI1 transcriptional complex includes: CREB-binding protein, RNA
polymerase II, and RNA Helicase A (RHA) [44, 115]. It has been previously reported
that RHA increases EWS-FLI1 mediated transcription, suggesting that these protein:
protein interactions are important for ES oncogenesis [44]. EWS-FLI1 binds to RHA in a
unique position where if inhibited it would not interfere with any other transcriptional or
RNA metabolism proteins (Figure 1.7) [44]. Based on this experimental discoveries RHA
inhibition is an attractive target for treating ES. Erkizan et al developed the small
17

molecule YK-4-279 as an inhibitor of RHA EWS-FLI1 binding. YK-4-279 binds RHA
inhibiting its ability to bind and interact with EWS-FLI1 at x-y micromolar
concentrations [116]. They also demonstrated that YK-4-279 treatment inhibits EWSFLI1 functionality. Luciferase reporter assays were conducted to demonstrate EWS-FLI1
activity at the NR0B1 promoter upon concentration dependent YK-4-279 treatment in
COS7 cells [116]. YK-4-279 was also shown to induce apoptosis and inhibit ES cell
growth [116]. Efficacy studies in ES xenografts displayed significant decreases in tumor
size compared to control showing potential use for YK-4-279 in the clinic [116]. Due to
poor clinical activity YK-4-279 is no longer being evaluated for the treatment of ES, an
analogue of YK-4-279, TK216, is currently being evaluated in a clinical trial [117].

Figure 1.7. YK-4-279 binds RHA inhibiting its interaction with EWS-FLI1 and
transcription of target genes.
1.3.4.2 Mithramycin (MTM)
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In efforts to discover an EWS-FLI1 inhibitor a 50,000-compound highthroughput screen was conducted at the National Cancer Institute (NCI) in 2011. Cell
based luciferase reporter screens in TC-32 ESFT cells identified MTM (Figure 1.8) as a
potent inhibitor of EWS-FLI1 [118]. MTM is a tricyclic polyketide that was originally
isolated from Streptomyces Argillaceous for its antibiotic activity but was later found to
have potent anti-tumor activity [119]. MTM was characterized based on its ability to
inhibit EWS-FLI1 activity in vitro using microarray expression profiling, qRT-PCR, and
immunoblot analysis. In vitro assays displayed MTM ability to inhibit expression of
downstream EWS-FLI1 targets at the mRNA and protein levels [60]. In vivo studies
included xenograft studies where MTM suppressed tumor growth in two different ESFT
models [118].
The success of this pre-clinical study prompted a phase I/II clinical study
of MTM in children and adults with refractory ES [120]. Results from the clinical trial
showed that MTM has a very narrow therapeutic window. At doses relevant to treat and
decrease tumor size in these patients, toxicity was prevalent [120]. The average maximal
MTM plasma concentration in patients was 17.8 ± 4.6 ng/mL. The average plasma
concentrations of MTM measured were extremely low compared to the sustained MTM
concentrations required to suppress EWS–FLI1 transcriptional activity in preclinical
studies at ≥50 nmol/L [120]. Patients displayed high levels of alanine aminotransferase
(ALT) and aspartate aminotransferase (AST), hallmarks of severe liver damage [120]. It
has been reported that MTM binds DNA specifically at GC sites, inhibiting the
transcription factor Sp1 from binding and regulating expression of thousands of genes
[121]. There is evidence that the inhibition of Sp1 by MTM is a substantial part of its
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associated toxicity [122]. These data have helped to guide the development of second
generation MTM analogues that can confer potent inhibition of EWS-FLI1 while
bypassing toxicities associated with MTM treatment.

Figure 1.8. MTM binds DNA and inhibits EWS-FLI1 mediated transcription.

Development of MTM analogues
To circumvent the toxicities associated with MTM (Figure 1.9) treatment
while exploiting its tumor regression properties, there has been a collective effort to
develop MTM analogues. Semisynthetic efforts have been employed to diversify the
structure of MTM into two classes of analogues MTMSA and MTM-oxime (MTMox)
analogues.

Figure 1.9. Structure of MTM.
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MTMSA analogues
In the first class of MTM analogues new compounds were complemented
by combinatorial biosynthetic procedures, where the genes of the biosynthetic pathway
of the drugs was altered in the bacteria themselves [123]. This method allows for the
generation of a bacterial strain that can mass produce the new analogue. Remsing et. al.
knocked out gene mtmW by insertional inactivation, which encoded a reductase enzyme
involved in the final ketoreductase step of MTM’s C3-side chain and total biosynthesis
[123]. The resulting mutant knockout strain, Streptomyces argillaceous M7W1, generated
3 novel MTM analogues, namely MTMSK, MTM SDK and MTMSA (Figure 1.10). Cell
viability studies in a panel of 60 human cancer cell lines revealed that MTMSK and
MTMSDK were several folds more cytotoxic than MTM [123]. These analogues were
also evaluated in vivo, demonstrating a decrease in tumor growth in both prostate and
ovarian tumor xenograft studies in mice [124, 125]. Due to off target toxicities associated
with MTMSK and MTMSDK treatment MTM was developed further for a more
selective analogue.
It has been previously reported that amide functionalization of the
carboxylic acid of the compound may produce MTMSA analogues with improved
cytotoxicity [126-128]. Amide conjugates were initially synthesized but showed little
cytotoxic activity in the A549 lung cancer cell line [124]. This result led to the
conjugation of larger aromatic amino acid resides tryptophan and phenylalanine,
MTMSA-TRP and MTMSA-PHE (Figure 1.10).
MTMSA-TRP and MTMSA-PHE demonstrated in vitro anti-cancer
activity similar to MTM [129]. In further mechanistic studies they were also shown to
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bind DNA and physically interact with EWS-FLI1 [1, 2, 130]. Further refinement of
these MTM analogues led to the development of MTMSA-PHE-TRP and MTMSA-TRPTRP (Figure 1.10) [131]. Mitra et al reported that both MTMSA-PHE-TRP and
MTMSA-TRP-TRP have potency similar to MTM in ESFT cells [131]. It was also
reported that MTMSA-PHE-TRP and MTMSA-TRP-TRP are more selective for cell
lines that express EWS-FLI1 than MTM and previously reported analogues [131].
Further studies are currently ongoing to determine efficacy and pharmacokinetics of
other analogues in xenograft mouse models of Ewing sarcoma.

Figure 1.10. Structures of MTMSA analogues.
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MTM oxime analogues
In the field of vaccine development there have been many attempts to
develop a semi synthetic approach where epitope functional groups are conjugated to
complex antigens to induce an immunological response. One such example was the
conjugation of peptide T-epitope to monosaccharide α-GalNAc carbohydrate antigen
[132]. This carbohydrate unit is presented on glycoproteins of adenocarcinoma cells, and
therefore was an antigen of interest for vaccination. The semi-synthetic conjugation of
peptide T-epitope to α-GalNAc was accomplished through a novel oxime linker group.
This oxime linker was reported as stable towards acids, bases, and enzymatic hydrolysis.
Olivomycin A belongs to the family of aureolic acid antibiotics that includes also
mithramycin, chromomycin A3 and duramycin [119]. Like MTM, olivomycin binds GC
rich regions on DNA in the minor groove, interfering with many cellular functions.
Because of this it has been of great interest to modify the chemical structures of these
compounds to design a class of anti-tumor chemotherapeutics. It has been reported that
similar strategies utilizing the stable oxime linker on different molecules [133, 134],
including olivomycin has been successful [126].
Liu et al utilized this chemistry to develop novel MTM analogues
(unpublished). This was accomplished through an oxime linker group conjugated to the
C3-side chain of MTM [126]. This chemistry was utilized to develop a library of over 50
mithramycin-oxime analogues. MTMox analogues are depicted in Figure 1.11
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Figure 1.11. Structures of MTMox analogues.

Hypothesis and specific aims of research
The long-term goal of this research effort is to develop novel MTM
analogues for targeted therapy against EWS-ETS transcription factors. The objective of
this work, to investigate molecular differences in the mechanism of action of analogues
compared to MTM. The central hypothesis was that structural differences in MTM
analogues result in physiochemical and molecular binding differences. MTM analogues
are less ionized allowing for less of an ionized fraction available for uptake into OATP
transporters. Additionally, molecular binding has implications for the advancement of
specific analogues that have improved specificity and efficacy against EWS-ETS
transcription factors. The rationale for this work was that novel MTM analogues will
target ETS transcription factors and increase the therapeutic window. The central
hypothesis was evaluated using the following specific aims.
Specific Aim 1: To determine ionization differences between MTM and
analogues and determine their substrate activity with OATP transporters.
The objective of this aim was to determine how structural differences
affect pKa of analogues and how this physiochemical property affects OATP transporter
affinity. To attain this objective, the working hypothesis was evaluated. The addition of
bulky aromatic side groups to MTM shield the aromatic core of MTM from ionization.
Those analogues that are less ionized at physiological pH (higher pKa) are less ionized,
making them less of a substrate of OATP mediated uptake into the liver. The rationale
for this aim was to identify MTM analogues that are less ionized at physiological pH in
hopes that this feature would increase their plasma half-life.
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The following experimental approach was used to evaluate the working
hypothesis. pKa values of MTM and analogues was used to determine relative ionization
constants. MTM and analogues were exposed to a range buffers at increasing pH (pH 38) and fluorescence of the aromatic core was documented. Shifts in fluorescence at each
pH was monitored and used to calculate the pKa of each analogue. Cytotoxic assays were
used to assess the relative differences in cytotoxicity, these assays were assessed by
growth inhibition index (GI50) in RKO cells transfected with a pIRES neo expression
vector. The GI50 of the control cell line RKO-pIRES was compared to RKO-OATP1B1
and RKO-OATP1B3. These cell lines do not express any EWS-ETS translocations but
were treated with MTM and analogues to evaluate their potential to uptake MTM and
analogues over a 72-hour cytotoxicity assay. To assess the possibility of MTM and
analogue OATP inhibition a competitive inhibition assay was designed and executed.
OATP expressing cell lines were co-treated with a known fluorescent substrate, 8-FcA
(8-(2-[Fluoresceinyl] aminoethylthio) adenosine-3', 5'-cyclic monophosphate) in
combination with rifampicin (an OATP inhibitor) MTM or MTM analogue. After
treatment, the fluorescence of 8-FcA was measured from the contents of lysed cells. To
assess the possibility of MTM and analogues plasma half-life being affected by the
presence of an OATP substrate, we then evaluated this possibility in vivo. Female
FVB/N mice with Oatp1a/1b knockout (Del(Slco1b2-Slco1a5)) and separately
humanized with OATP1B1 (Tg(APOE-SLCO1B1)), OATP1B3 (Tg(APOE-SLCO1B3))
and OATP1B1/1B3 transgenes, were pre-treated with rifampicin an hour later MTM or
MTMSA-Trp-A10 was given intravenously.
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Specific aim 2: MTM analogues bind DNA and physically interact with EWSFLI1
To determine mechanistically MTM and analogue interaction with EWSETS transcription factors. The objective of this aim was to determine if MTM and
analogues displacement and/or stabilize ETS-EWS transcription factors at their binding
sites. The working hypothesis was based on preliminary data collected by Hou et. al. that
MTM binds GC repeats on DNA causing disruption of EWS-ETS activity. We
hypothesize that MTM analogues with large hydrophobic side chains will bind DNA and
physically interact with EWS-ETS transcription factors. Additionally, this disruption or
stabilization at the site of transcription factor binding will interfere with the
transcriptional regulator RNA polymerase 2 (RNAPII) and cause double stranded DNA
(dsDNA) breaks specifically in EWS-ETS expressing cell lines. dsDNA breaks are
cytotoxic to cells but can be repaired through the cell’s main DNA repair mechanism the
enzyme PARP11. Cytotoxic dsDNA breaks can be sustained by combining MTM or
MTM analogue with a PARP1 inhibitor. The rationale for this proposed aim is to
understand the physical interaction MTM and analogues have with EWS-ETS
transcription factors. These analogues that show a specific physical interaction with
EWS-ETS transcription actors will be more suitable for the development of an MTM
analogue with improved specificity.
The following experimental approach was used to evaluate the working
hypothesis. Time-resolved fluorescent energy transfer studies were designed and
conducted to delineate ERG displacement in the presence of MTM or analogue. Cellular
thermal shift assays (CETSA) were conducted to delineate a physical interaction between
MTM analogue and EWS-FLI1. Protein expression studies were carried out, upon
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treatment with MTM or analogue, to show differences in DNA damage markers and to
show RNAPII markers of disrupted transcription. A reduction in the expression of
phosphorylated Serine 2 on the C-terminal domain (CTD) of RNAPII led to the
consideration of mRNA expression studies. mRNA expression studies of CDK12,
BRCA1, FANC1 and FANCD2 showed a reduction in expression after treatment with
MTM analogues specifically in EWS-FLI1 expressing cell lines. This result showed that
MTM and analogues play a part in down regulating genes involved in DNA damage
repair leading to the completion of cytotoxic combination studies, combining MTM or
MTM analogue with the PARP1 inhibitor olaparib. To evaluate the synergistic effect
seen in cells in vivo xenograft studies were conducted in athymic NU/NU mice
combining olaparib and MTMSA-TRP.
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CHAPTER 2. DIFFERENTIAL PHYSIOCHEMICAL PROPERTIES OF MTM
ANALOGUES ALLOW FOR PREFERENTIAL UPTAKE INTO OATP
Introduction
The liver is one of the most important organs involved in metabolism and
excretion of xenobiotics [135]. In addition, the liver consists of a barrier for the entry of
xenobiotics into systemic circulation [135]. Organic anion transporting polypeptides
(OATPs) are transmembrane proteins expressed on the sinusoidal membrane of
hepatocytes [136]. They are essential in the disposition of drugs, xenobiotics, and a
variety of endogenous substrates. OATPs are a part of the solute carrier superfamily
(SLCO) and 11 OATPs are expressed in humans. Both SLCO1B1 and SLCO1B3 genes
are located on the short arm of chromosome 12 (gene locus 12p12) and are translated
into OATP1B1 and OTP1B3 [137] . OATP1B1 and OATP1B3 proteins share similar
amino acid sequences, with 80% homology [138]. OATP1B1 and OATP1B3 are both
highly expressed in normal human liver and localized on the basolateral membrane of
hepatocytes [138]. However, OATP1B1 and OATP1B3 are expressed differently in the
liver. OATP1B3 is expressed primarily around the central vein of hepatic lobules [138],
and OATP1B1 is expressed diffusely throughout liver sections [138, 139]. In addition,
OATP1B1 and OATP1B3 act as anion exchangers to facilitate transport of their
substrates into the hepatocyte for further metabolism.
A significant adverse effect of treatment with chemotherapy is
hepatotoxicity. Close monitoring of liver function is suggested for patients receiving
chemotherapeutic treatment. Chemotherapy induced liver dysfunction is assessed by the
NCI as elevations of serum enzyme activities of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl
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transferase (GGT) [140]. In recent clinical trials patients with recurrent and refractory
Ewing sarcoma were treated with MTM. This study was halted due to dose limiting
hepatotoxicity [120]. In addition, MTM has also been shown to be rapidly cleared by the
liver within 5-6 hours after administration [120]. Because MTM is rapidly distributed
into peripheral tissue compartments, its route of clearance is an important aspect of its
pharmacokinetic properties. Many xenobiotics are cleared by the liver which can lead to
accumulative toxicities in that organ. In addition, there is also concern that elimination of
xenobiotics in the liver can result in rapid clearance and less exposure of the compound
to its target. Distribution of xenobiotics is mediated by active, facilitated and/or passive
mechanisms. Passive diffusion through the plasma membrane is normally a function of
the xenobiotics’ lipophilicity. In the hepatocyte numerous membrane transporters are
expressed on the basolateral and apical membranes have been identified. These
transporters facilitate the efflux and influx of xenobiotics and endogenous substrates.
Preliminary results collected by Dr. Joseph Eckenrode demonstrated that at effective
levels, when mice were treated with the analogue MTMSA-TRP-TRP there was no
obvious hepatotoxicity measured by ALT, AST and ALP enzymes within the serum [1].
Together these findings led to the question of what role do OATP transporters play in the
disposition of MTM and its analogues. To answer this question the ionization constant
(pKa) of MTM and its analogues was assessed and based on their pKa assays were
designed to understand their interaction with OATP1B1 and OATP1B3. Table 2.1
depicts OATPs that are expressed in human liver.
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Table 2.1 OATP transporters expressed in human and mouse liver and their function.
OATP expression in humans
OATP

Normal tissue expression Reference(s)

OATP1B1

Liver

[138, 141, 142]

OATP1B3

Liver

[143, 144]

OATP2B1

Liver

[145]

Blood-brain barrier

[146]

Enterocytes

[145]

Placenta

[147]

Heart

[148]

OATP expression in mice
OATP

Normal tissue expression

Reference(s)

Oatp1a/b

Liver

[149]

Oatp1b2

Liver

[150]

Oatp1a4

Brain

[151]

Liver

[152]

Because MTM is highly ionized we hypothesized that differential
physiochemical properties of MTM analogues affect their affinity for uptake into OATP
transporters, thereby allowing them to have longer plasma half-lives in plasma and
giving them more opportunity to target tumor tissue before being metabolized.
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Materials and Methods
Estimation of ionization constants (pKa)
2.2.1.1 Preparation of buffer solutions
The pH of the buffers was measured with a glass electrode at room
temperature All the solutions were prepared with Milli-Q water. The 0.1 M standard
solution of HCl (Sigma, St. Louis, MO) and NaOH (Sigma, St. Louis, MO) were used to
adjust the pH of each buffer.
2.2.1.1.1 ACETIC ACID/SODIUM ACETATE PH 3.0 TO 5.0
Sodium acetate (Sigma, St. Louis, MO) solution (100 mL of 0.1 M) was
prepared by dissolving powder (820.3 mg, 10 mM) in 100 mL of Milli-Q water. Each
buffer solution was prepared by diluting 25 mL of 0.1 M sodium acetate solution with 25
mL of Milli-Q water while stirring at room temperature. The pH was adjusted to the
required value (pH 3.0, 4.0 or 5.0) by adding 0.1 M HCl (Sigma, St. Louis, MO) standard
solution with a glass pipette. Finally, the ionic strength of the buffer solutions was
adjusted to 0.1 M by adding KCl [153].
2.2.1.1.2 POTASSIUM HYDROGEN PHOSPHATE/DIPOTASSIUM HYDROGEN PHOSPHATE PH 6.0
TO 8.0.
Potassium hydrogen phosphate (Thermo Fisher Scientific, Waltham, MA)
(1 L of 0.05 M) solution was prepared by dissolving KH2PO4 (6.8 g, 50 mM) in 1 L of
Milli-Q water. Each buffer solution was prepared by dissolving 25 mL of 0.1 M KH2PO4
and was stirred at room temperature an Erlenmeyer flask. The pH was adjusted to the
required value (pH 6.0, 6.5, 7.0, 7.5, 8.0 or 8.5) by adding 0.1 M HCl (Sigma, St. Louis,
MO) or 0.1 M NaOH (Sigma, St. Louis, MO) standard solution with a glass pipette. The
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volume was adjusted to 50 mL with Milli-Q water. Finally, the ionic strength of the
buffer solutions was adjusted to 0.1 M by adding KCl [153].
2.2.1.2 Ionization constant estimation experimental procedure
Each compound was weighed and dissolved in Dimethyl sulfoxide
(DMSO) (Sigma, St. Louis, MO) (500 µM stocks). Polystyrene flat bottom black 384well microplates (Thermo Fisher Scientific, Waltham, MA) were loaded with 98 µL of
buffer solutions of increasing pH (ranging from 3 to 8.5). Then 2 µL of the compound
stock solutions were added to each well with a displacement micropipette. The final
concentration of the analogue in each well was 10 µM. One blank solution was prepared
for each buffer by adding 2 µL of DMSO to 98 µL of the corresponding buffer solution
in the well. The 384-well plate was incubated at 37°C and shaken for 10 minutes prior to
reading. Plates were then loaded into a UV-spectrophotometer (BMG Labtech Clariostar
microplate reader, Ortenberg, Germany). Fluorescence spectra emission scans (Ex.40020) were recorded between 483 nm and 738 nm (2 nm resolution) [153].
2.2.1.3 Data analysis

Fluorescence intensity values across wavelengths (483 nm - 738 nm) were
exported to a spreadsheet (Excel, Microsoft) and values were corrected by subtracting
the fluorescence spectra of blank solutions. The maximum fluorescence was extracted
and plotted vs. its corresponding pH. Non-linear regression (GraphPad Prism 8.0, La
Jolla, CA) was used to fit a sigmoid Emax model to the data. This analysis determined the
pKa as the pH at which the half maximum increase in fluorescence occurred [153]. The
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equation: 100/(1 + 10)−1(𝑝𝐻−𝑝𝐾𝑎) was used to determine percent ionization of each
compound.
Cell Lines and reagents
RKO (colon carcinoma) cells were previously stably transfected with
OATP1B1 and OATB1B3 cDNA, inserted in the multiple cloning sites of the
pIRESneo2 vector (Clontech, Mountain View, CA) (Monks et al., 2007; Daily et al.,
2010). The RKO cell lines were grown in DMEM (Sigma, St. Louis, MO) prepared with
10% (v/v) heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Flowery
Branch, GA), non-essential amino acids (Sigma, St. Louis, MO) (1 %) and penicillinstreptomycin (VWR, Radnor, PA) (10X) were added in the media. Additionally, DMEM
media was supplemented with Geneticin (VWR, Radnor, PA) (G418, 800 μg/mL) and
non-essential amino acids (1 %) were added to the RKO growth media. DMEM was
prepared with 2 g/L sodium bicarbonate (Sigma, St. Louis, MO), pH was adjusted to 7.2
and filtered with 0.2 µm filters (Corning, Corning, NY) prior to use. After mixing and
pH adjustment, media was then filtered under sterile conditions in a biosafety hood.
Growth media was stored at 4°C between uses and kept sterile.
OATP expression validation
RKO-pIRES, RKO-OATP1B1 and RKO-OATP1B3 cells were seeded in
6-well plates (VWR, Radnor, PA), at a density of 250,000 cells/well. Cells were washed
with PBS (Sigma, St. Louis, MO), pH 7.4 and 500 µL of 0.05% Trypsin with 0.53mM
EDTA (Corning, Corning, NY) was added. After a 2 - 3 minutes’ incubation, cells
detached from the plate and 1mL of fresh DMEM (Sigma, St. Louis, MO) media was
immediately added. Cells were collected in 1.5 mL tubes on ice and centrifuged to a
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pellet at 1200 g for 5 minutes. Supernatant was removed and cell pellets were lysed with
600 µL of RLT lysis buffer (Qiagen, Hilden, Germany). Lysates were centrifuged
through QIAshredder inserts for complete cell disruption (Qiagen, Hilden, Germany).
RNeasy mini spin columns were used to isolate pure, total RNA (Qiagen, Hilden,
Germany). RNA concentrations were measured using NanoDrop 2000 Spectrometer
(Thermo Fisher Scientific, Waltham, MA) and a 100 ng/µL stock solution was prepared.
RNA (1 µg) was used to prepare cDNA with an iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). qRT-PCR reactions were conducted using Maxima SYBR green Taq
DNA Polymerase (Thermo Fisher Scientific, Waltham, MA). EpMotion5070
(Eppendorf, Hamburg, Germany) robot was used to mix reactions in 384-well PCR
plates (Thermo Fisher Scientific, Waltham, MA) and thermocycling was completed on a
QuantStudio 7 Flex (Thermo Fisher Scientific, Waltham, MA). Primers for SLCO1B1
(forward: AGCAGACGCACAACCTTCAGA) (reverse:
GCTGAGTGACAGAGCTGCCA), SLCO1B3 (forward:
CCTTCACAGTTAAATTACATGGTC) (reverse:
TATTCATTTCATATAAAACTGTATACC) and 18S (forward:
GCTTAATTTGACTCAACACGGGA) (reverse:
AGCTATCAATCTGTCAATCCTGTC) was used as the housekeeping gene for
comparing relative transcript (mRNA) expression, using ΔΔCT calculation, of target
genes. All primer sequences (IDT, Coralville, IA) were verified to amplify a single
amplicon of appropriate size by gel electrophoresis and melting curve analysis.
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Cell viability of OATP expressing cell lines after MTM analogue treatment
Cells were seeded in clear 96-well plates (VWR, Radnor, PA) at 5,000
cells/well. Cells were then allowed to adhere to the plates for 24 hours, cells in duplicate
wells were treated with half-log increments of respective compounds (0 nM and 3 nM –
10 µM). Working stocks were prepared from an initial 10 mM drug stock diluted in
either 100% ethanol or DMSO (Sigma, St. Louis, MO). All wells contained a final
concentration of 0.01% (v/v) respective organic solvent. Following treatment, cell
viability was measured for vehicle control (Day 0) wells. Cell viability was measured in
the remaining wells after 72 hours of incubation with compound or vehicle control (Day
3). For viability measurements, 0.1 mM resazurin (Sigma, St. Louis, MO) was added to
wells. After 3 hours of incubation at 37 °C, fluorescence readings (Em. 560 nm, Ex. 590
nm) were recorded using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale,
CA).
Intracellular concentration of MTM and analogues
RKO-pIRES, RKO-OATP1B1 and RKO-OATP1B3 cells were seeded at
a cell density of 1×106 in 6-well plates and allowed to attach to plate for 24 hours. MTM
or MTMSA-TRP-TRP were diluted in warm uptake buffer (NaCl 136mM, KCl 5.3mM,
KH2PO4 1.1mM, MgSO4 0.8mM, CaCl2 1.8mM, D-Glucose 11mM, HEPES 10mM) to a
final concentration of 10 µM. Cells were washed with PBS and incubated in drug
dilutions for 2, 5, 10 or 15 minutes. Uptake buffer was then collected, and cells were
scraped and lysed in water. Intracellular concentration of MTM and MTMSA-TRP-TRP
in cell lysates was measured by LC-MS/MS.
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Competitive inhibition studies
Approximately 48 hours following seeding stable cell lines, cells were
aspirated of media and washed three times with PBS (Sigma, St. Louis, MO). The cells
were then incubated at 37°C in uptake buffer (116.4 mM NaCl, 5.3 mM KCl, 1 mM
NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-Glucose, 20 mM HEPES, adjusted to pH 6 or pH
7.4) for 10 minutes to equilibrate with the buffer; inhibitor was not present during this
period. Following the 10-minute equilibration period, the uptake buffer was aspirated,
and the experiment was initiated by the administration of either substrate, 8-FcA (Biolog,
Germany) and vehicle, 0.01% DMSO (Sigma, St. Louis, MO) or substrate and OATP
inhibitor, rifampicin (VWR, Radnor, PA) or MTM analogue. For competitive inhibition
studies 8-FcA (2.5 µM) was diluted in uptake buffer immediately added to cells, cells
were then incubated in the substrate solution for 10 minutes. To determine inhibition of
8-FcA uptake the inhibitors were prepared to a final vehicle concentration of 0.01%
DMSO. A vehicle control plus seven half log concentrations of inhibitor were used for
each assay. Cellular uptake of 8-FcA was terminated by aspirating the substrate solution
and washing cells with ice cold PBS three times. Cell content was extracted using a
50:50 v/v solution of methanol: Tris-EDTA (10 mM, 1 mM), pH 8.0 for approximately
10 minutes. An aliquot of the extract was transferred to black clear bottom 96-well plates
(VWR, Radnor, PA) for fluorescence measurements. Relative fluorescence of cell
extracts was determined by spectrofluorometer (Ex. 485 nm, Em. 535 nm) using a BIOTEK Synergy H1 Hybrid plate reader (BioTek, Winooski, VT). Another aliquot was also
transferred and used to quantify total protein of each sample using the Bicinchoninic acid
method (BCA) (Thermo Fisher Scientific, Waltham, MA). Fluorescence of the substrate,
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8-FcA, in competition with rifampicin, MTM or MTM analogue was normalized by total
protein was plotted vs. inhibitor concentration. Non-linear regression (GraphPad Prism
8.0, La Jolla, CA) was used to fit a sigmoid Emax model to the data. This analysis
determined the EC50 as the concentration at which the half maximum decrease in
fluorescence occurred.
Pharmacokinetic studies in transgenic Oatp knockout mice
Female FVB/N mice with Oatp1a/1b knockout (Del(Slco1b2-Slco1a5))
and separately humanized with OATP1B1 (Tg(APOE-SLCO1B1)), OATP1B3
(Tg(APOE-SLCO1B3)) and OATP1B1/1B3 transgenes, individually, were purchased
from Taconic Biosciences (Hudson, NY). Rifampicin (VWR, Radnor, PA) was dissolved
in dextrose (Sigma, St. Louis, MO) 5% in water (D5W) and administered to mice by oral
gavage (20 mg/kg), an hour later MTM and MTMSA-TRP-TRP were administered as a
cassette by intravenous bolus (IV) at doses of 0.3 mg/kg. Saphenous bleeds were
collected between 5 minutes and 3 hours. Pipette tips and needles were primed with
heparin as an anti-coagulant. Whole blood samples were centrifuged at 3000xg to rapidly
collect plasma and were immediately frozen on dry ice and stored at -80°C until analysis.
Sample extracts were prepared by Dr. Joseph Eckenrode and analyzed by HPLCMS/MS. All animal studies were conducted under approved institutional animal care and
use [1].
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Results and discussion
Concentration of drug has minimal effect on pKa
To assess whether concentration of MTM or analogue influenced the pKa
a dose response experiment was conducted. MTM, MTMSA-PHE-TRP and MTM24
were diluted in DMSO to 1, 3, 10, 20 or 30 µM and a pKa curve was generated for each
drug concentration. In all compounds at the 1 µM and 3 µM concentrations the final
concentration of drug was too low to estimate an accurate pKa measurement. In Figure
2.1 panel A. MTM pKa measured at 10, 20 and 30 µM showed similar results to previous
experiments and published reports. MTMSA-PHE-TRP and MTMox24 Figure 2.1 panel
B and C respectively, measured at 10, 20 and 30 µM demonstrated a gradual increase in
pKa as concentration was increased. Refer to Table 2.2 for estimated pKa measurements.
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Figure 2.1. Experimentally determined pKa measurements. MTM (A), MTMSA-PHETRP (B) and MTMox24 (C) pKa measurement is affected by drug concentration. pKa
values listed in Table 2.2 below.
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Table 2.2. Experimentally determined pKa measurements with respect to concentration.
Compound

MTM

MTMSA-PHE-TRP

MTMox24

Concentration (µM)
1
3
10
20
30
1
3
10
20
30
1
3
10
20
30

Measured pKa
3.64
2.72
4.87
4.99
4.93
3.97
6.68
6.84
7.03
7.39
3.49
7.51
6.31
7.19
7.62

Ionization constant of MTM and analogues changes with addition of Mg2+
As previously stated, for MTM to bind DNA and exerts its cytotoxic
effects on cells it must bind DNA as a divalent metal ion (Mg2+)-coordinated dimer
[154]. Here we investigated differences in the estimated pKa of select MTMox analogues
with and without Mg2+ included in the pH buffer. In Table 2.2Error! Reference source n
ot found. all analogues except MTMox4 tested demonstrate a decrease in pKa after the
addition of Mg2+.
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Table 2.3. Experimentally determined pKa values of MTMox compounds with and without
Mg2+ in pH buffers
Compound

pKa
-Mg2+
4.93
4.38
5.61
4.11
6.15
6.91
6.33
6.15
6.32
4.62
6.67
5.65
6.82
5.47
5.86
5.44
5.92
4.69
5.91
5.14

pKa shift

+Mg2+
MTM
MTMox3
MTMox4
MTMox19
MTMox20
MTMox23
MTMox24
MTMox31
MTMox32
MTMox33

-0.55
-1.5
+0.759
-0.76
-1.7
-1.02
-1.35
-0.42
-1.23
-0.77

Estimation of ionization constants (pKa)
To calculate the ionized fraction available for uptake by OATP
transporters for each analogue, we determined the pKa of MTM and each analogue. Our
results suggest that bulky substitutions have an apparent shielding effect that leads to an
increase in pKa. This is depicted in Figure 2.2 which shows that addition of tryptophan
and tryptophan dipeptide to MTMSA leads to incremental shift of the pKa as aromatic
substitutions are added to MTM. In Figure 2.3, select MTMox compounds estimated pKa
demonstrate a shift as well from a MTMox3 which possesses the oxime linker without
additional side groups to MTMox20 and MTMox24 which are the oxime equivalents to
MTMSA-TRP and MTMSA-TRP-TRP. In Figure 2.3 the shift in pKa is less pronounced
than it is in the MTMSA analogues. Table 2.4 and Table 2.5 lists the pKa and the percent
ionization of all MTMSA and MTMox tested at physiological pH (7.4). In both classes of
analogues (MTMSA and MTMox) there is a significant increase in pKa when aromatic
amino acids are substituted at the C-3 side chain of MTM.

42

Normalized Relative Fluorescence

150
100

MTM
MTMSA
MTMSA-TRP
MTMSA-TRP-TRP

50
0
4

6

8

10

pH

-50

Normalized Relative Fluorescence

Figure 2.2. pKa shift as aromatic amino acids substitutions are added to the MTMSA C-3
side chain. MTM (squares) has a pKa of 4.9, MTMSA (circles) has a pKa of 5.41, MTMSATRP (triangles) has a pKa of 6.79 and MTMSA-TRP-TRP (open squares) has a pKa of 7.11.
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Figure 2.3. pKa shift as aromatic amino acids substitutions are added to the MTMox C-3
side chain. MTM (open squares) has a pKa of 4.9, MTMox3 (circles) has a pKa of 5.41,
MTMox20 (squares) has a pKa of 6.79 and MTMox24 (triangles) has a pKa of 7.11.
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Table 2.4. MTMSA analogues ionization constants and percent ionization at physiological
pH.

Compound

Ionization
constant
(pKa)

CI
(95%)

Percent
ionized
at pH
7.4

MTM

4.89

4.81 5.04

99.7

MTMSA

5.40

5.27 –
5.54

99.0

MTMSK

5.16

5.08 5.27

99.4

MTMSA-PHE

6.41

wide

90.7

MTMSA-TRP

6.79

6.64 6.95

80.3

MTMSA-PHETRP

7.17

7.06 7.29

62.9

MTMSA-TRPTRP

7.11

6.96 7.33

66.1
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Structure

Table 2.5. MTM-oxime analogues ionization constants and percent ionization at
physiological pH.

Compound

Ionization
constant
(pKa)

CI
(95%)

Percent
ionized
at pH 7.4

MTM

4.89

4.81 - 5.04

99.7

MTMox1

5.94

5.90 - 6.04

96.6

MTMox2

5.86

5.78 - 5.95

97.2

MTMox3

5.58

5.51 - 5.65

98.5

MTMox4

6.11

6.05 - 6.24

95.1

MTMox5

7.77

6.30 - 6.98

29.9

45

Structure

Table 2.5 continued

MTMox5E

6.64

5.70 - 7.56

85.2

MTMox7

5.84

5.79 - 5.89

97.3

MTMox7E

5.89

5.83 - 5.94

97.0

MTMox9

5.36

5.05 - 5.68

99.1

MTMox10

6.12

5.99 - 6.26

95.0

MTMox11

5.80

5.83 - 8.07

97.5
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Table 2.5 continued

MTMox12

6.15

6.02 - 6.28

94.7

MTMox14

5.98

5.88 - 6.11

96.3

MTMox14E

6.39

6.39 - 6.63

91.1

MTMox15

6.07

5.95 - 6.19

95.5

MTMox16

5.71

5.59 - 5.80

98.0
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Table 2.5 continued

MTMox17

5.92

5.87 - 5.98

96.8

MTMox17E

5.83

5.78 - 5.88

97.4

MTMox18

6.39

6.09 - 6.70

91.1

MTMox19

6.33

6.39 - 7.02

92.2

MTMox19E

7.01

6.84 - 7.17

71.1

MTMox20

6.32

6.03 - 6.62

92.3
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Table 2.5 continued

MTMox21

6.25

6.13 - 6.63

93.4

MTMox22

6.67

6.59 - 6.99

84.3

MTMox23

6.67

6.46 - 6.89

84.3

MTMox24

6.82

6.58 - 7.05

79.2

MTMox25

6.52

6.03 - 7.27

88.4
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Table 2.5 continued

MTMox26

6.39

6.21 - 6.58

91.1

MTMox27

6.36

6.21 - 6.51

91.6

MTMox29

6.01

5.87 - 6.28

96.1

MTMox30

6.12

5.92 - 6.32

95.0

MTMox31

5.85

5.68 - 6.04

97.3

MTMox32

5.91

5.84 - 5.97

96.9
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Table 2.5 continued

MTMox33

5.91

5.65 - 6.18

96.9

MTMox34

6.11

5.87 - 6.35

95.1

Validation of expression of OATP in stably transfected RKO cell lines
The apparent pKa data strongly suggested that the interaction of MTM
analogues with OATP transporters may be altered, which would manifest in decreased
liver uptake. To assess whether MTM and its analogues interacted with OATP we used
RKO cell lines which were previously transfected with OATP [155]. Before undertaking
those experiments, we assessed OATP transporter expression or lack thereof in these
RKO cell lines by assessing the mRNA expression of (SLCO1B1) OATP1B1 and
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(SLCO1B3) OATP1B3 in each cell line. As expected, RKO cells transfected with the
empty vector had no detectable expression of either transporter after 40 RT-PCR cycles.
In comparison RKO cells that harbored vectors that expressed the genes SLCO1B1 and
SLCO1B3 mRNA expression was detected after 24 and 27 cycles, respectively.
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Figure 2.4. Validation of mRNA expression of OATP1B1 in transfected RKO cells. A
ΔΔCT calculation was used to determine relative mRNA expression from sybr-green qRTPCR estimated CT values and plotted. Error bars represent SEM of 3 biological replicates.
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Figure 2.5. Validation of mRNA expression of OATP1B3 in transfected RKO cells. A
ΔΔCT calculation was used to determine relative mRNA expression from sybr-green qRTPCR estimated CT values and plotted. Error bars represent SEM of 3 biological replicates.
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Direct measurement of intracellular uptake by OATP expressing cell lines
To determine whether MTM and analogues are transported by OATP, we
attempted to directly measure their intracellular concentrations following incubation with
10 µM MTM, MTMSA-TRP, MTMSA-TRP-TRP and MTMox24 for 2, 5, 10 and 15
minutes. Cells lysates were then processed and analyzed by LC-MS/MS. These analyses,
however, did not yield any interpretable data due to the relatively low ionization of these
compounds and the correspondingly high lower limit of quantitation. To overcome this
limitation, we chose to assess the intracellular concentrations using indirect methods.
Competitive Inhibition of OATP mediated uptake of MTM and analogues
To determine if MTM interacts with OATP1B1 and OATP1B3, we
designed a competitive inhibition assay. In this assay, we used the fluorescent OATP
substrate 8-FcA as a probe at a fixed concentration (2.5 µM). The intracellular
fluorescence was assessed in the OATP expressing cell lines (RKO-OATP1B1 and
RKO-OATP1B3) in the absence or presence of increasing MTM or MTM analogue
concentrations. The OATP inhibitor rifampicin was used as a positive control. Based on
this design, we expected that analogues with increased interaction with the transporter,
would decrease 8-FcA cellular uptake, which would be estimated by the decreased
fluorescence readout with increasing MTM concentrations. Non-linear regression was
used to estimate the IC50 as a comparative parameter across all analogues. Following a
10-minute incubation, cells were washed, lysed and the fluorescence of 8-FcA was
measured. This experiment was conducted in uptake buffer at pH 6 and at pH 7.4 to
assess changes in interaction based on the ionization shift of the tested compounds. We
expected that increased ionization (analogues with a lower pKa) would manifest to a
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lower IC50. The experimental results with MTMSA analogues are reported in Table 2.6
(pH 6) and Table 2.7 (pH 7.4). As expected, rifampicin and MTM which are highly
ionized at pH 6 compete with 8-FcA for entry into the cell via OATP transporters,
Conversely, analogues with bulky hydrophobic side chains (MTMSA-PHE, MTMSATRP, MTMSA-PHE-TRP and MTMSA-TRP-TRP) there is a much smaller ionizable
fraction of drug available for uptake via OATP transporters. These analogues with larger
more hydrophobic side groups do not compete as much for entry with 8-FcA, therefore it
takes more drug to reach an IC50. At pH 7.4, which is physiological pH rifampicin and
MTM are completely ionized meaning all the drug present is available for uptake via
OATP. Although the ionizable fraction of the MTMSA analogues does increase with pH
the same trend is demonstrated at pH 7.4 as with pH 6, there is less drug available for
entry into OATP allowing for more drug required to reach an IC50. Table 2.9 (pH 7.4)
demonstrates results generated when cells were treated with MTMox analogues. In
general, these analogues demonstrated similar results to the MTMSA analogues. Those
analogues that are more ionized competed more for entry via OATP than that of the
bulkier conjugated analogues that were less ionized. Collectively, these data suggest that
MTM inhibits the uptake of the OATP substrate 8-FcA more efficiently than its
analogues that are less ionized. However, these data do not directly demonstrate whether
MTM and its analogues are substrates of OATP transporters.
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Table 2.6. OATP mediated uptake of 8-FcA in the presence of select MTMSA analogues and the prototypical OATP inhibitor,
rifampicin, in uptake buffer at pH 6.

Compound

pKa

Percent
Ionized
(pH 6)

RKO-OATP1B1

RKO-OATP1B3
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IC50
IC50
CI (95%)
p-value
CI (95%)
p-value
(µM)
(µM)
1.9
100
1.53
1.39 - 1.68
0.998
0.958 - 1.12
Rifampicin
4.9
92.6
1.13
0.998 - 1.29
0.9999
1.55
1.22 - 1.97
0.9997
MTM
6.8
13.7
13.57
5.94 - 38.9
0.8998
12.11
3.82 - 64.9
0.9708
MTMSA-TRP
6.4
28.5
12.12
3.78 - 63.96
0.8617
16.18
3.58 - 65.7
0.9439
MTMSA-PHE
5.9
32.56
14.05 - 177.7
0.6059
32.16 13.92 - 170.5
0.7060
MTMSA-TRP-PHE 7.2
7.4
22.85
15.67 - 35.81
0.6997
50.48 27.69 - 142.3
0.7481
MTMSA-TRP-TRP 7.1
Statistical comparisons were by one-way ANOVA vs. the rifampicin treated samples with adjustment for multiple comparisons.

Table 2.7. OATP mediated uptake of 8-FcA in the presence of select MTMSA analogues and the prototypical OATP inhibitor,
rifampicin, in uptake buffer at pH 7.4.
Compound

pKa

Percent
Ionized
(pH 7.4)

RKO-OATP1B1

RKO-OATP1B3
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IC50
IC50
CI (95%)
p-value
CI (95%)
p-value
(µM)
(µM)
1.9
100
1.03
0.92 - 1.15
1.60
1.43 - 1.79
Rifampicin
0.9999
0.9998
4.9
99.7
1.02
0.923 - 1.14
2.52
1.83 - 3.48
MTM
0.9799
0.9986
6.8
79.9
6.02
2.39 - 16.83
5.98
2.61 - 14.82
MTMSA-TRP
0.9633
0.9944
6.4
90.9
5.36
1.66 - 19.5
5.34
1.47 - 22.4
MTMSA-PHE
0.6480
0.7465
61.3
32.77 11.85 - 1348
32.37 11.47 - 1047
MTMSA-PHE-TRP 7.2
0.7362
0.7849
66.7
9.9
wide
44.25
wide
MTMSA-TRP-TRP 7.1
Statistical comparisons were by one-way ANOVA vs. the rifampicin treated samples with adjustment for multiple comparisons.

Table 2.8. Estimated pKa and OATP mediated transport of 8-FcA with select MTMox analogues in uptake buffer at pH 6.

Compound

pKa

Percent
Ionized at
(pH 6)

RKO-OATP1B1

RKO-OATP1B3

Rifampicin
MTM
MTMox17

1.9
4.9
5.9

100
92.8
55.7

IC50
(µM)
1.53
1.03
4.85

MTMox20

6.3

33.4

4.37

3.31 - 5.79

0.9950

3.99

3.03 - 5.27

0.9997

MTMox24

6.8

13.7

9.98

7.28 – 13.93

0.9645

15.23

8.93 – 28.3

0.9336

CI (95%)
1.39 - 1.68
0.92 - 1.14
3.36 – 8.31

CI (95%)

p-value

0.9997
0.0009

IC50
(µM)
0.998
2.52
3.11

0.958 - 1.12
1.83 - 3.48
2.20 – 5.29

0.9997
0.0008

p-value
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0.0008
MTMox25
6.5
24
10.76 9.04 - 13.19 0.0009
11.23
8.20 - 17.04
Statistical comparisons were by one-way ANOVA vs. the rifampicin treated samples with adjustment for multiple comparisons.

Table 2.9. Estimated pKa and OATP mediated transport of 8-FcA with select MTMox analogues in uptake buffer at pH 7.4.

Compound

pKa

Percent
Ionized at
(pH 7.4)

RKO-OATP1B1

RKO-OATP1B3

Rifampicin
MTM
MTMox17

1.9
4.9
5.9

100
99.6
96.9

IC50
(µM)
1.03
1.02
3.26

MTMox20

6.3

92.6

4.39

1.79 – 11.17

0.9527

4.05

1.67 – 10.11

0.9985

MTMox24

6.8

79.9

5.32

3.90 - 7.30

0.9536

5.36

4.02 - 7.18

0.9925

CI (95%)
0.92 - 1.15
0.923 - 1.14
2.82 - 3.86

CI (95%)

p-value

0.9999
0.0034

IC50
(µM)
1.60
2.52
3.24

1.43 - 1.79
1.83 - 3.48
2.90 - 3.69

0.9997
0.001

p-value
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0.0035
0.0013
MTMox25
6.5
88.8
4.52
3.91 - 5.35
4.51 3.84 - 5.45
Statistical comparisons were by one-way ANOVA vs. the rifampicin treated samples with adjustment for multiple comparisons.

Cell Viability of MTM and analogues in OATP expressing cells as an indirect
measure to assess drug uptake in OATP expressing cells.
The cytotoxic activity of MTM and its analogues is manifested via their
DNA binding, which requires cellular entry. To indirectly assess the penetration of MTM
and its analogues, we performed a cytotoxicity assay in RKO cells expressing pIRES
empty vector, pIRES-OATP1B1 and pIRES-OATP1B3. These cells do not express any
ETS oncogenic fusions but were used to demonstrate that MTM and analogues permeate
these cells via the expressed transporters. Cell viability was measured following a 72hour treatment with increasing concentrations of MTM or MTM analogues. The dose
response data were analyzed via nonlinear regression using a sigmoid-Emax model to
estimate the GI50 for each compound (Table 2.10 and Table 2.11). Here we used
MTMSA (Table 2.10) and MTMox (Table 2.11) analogues with substitutions that led to
a shift in pKa. As reported in the tables, the variability (cf, confidence intervals) of the
GI50 estimation led to non-significant p-values when performing two-way ANOVA.
However, qualitatively, observations of the results can provide some insights. MTM was
the most cytotoxic compound tested and it was comparatively more toxic in cells
expressing OATPs. This suggests that uptake of MTM by OATPs in the RKO-OATP1B1
and RKO-OATP1B3 cells translated to an apparent increase in cytotoxicity and a lower
GI50. In comparison to MTM, bulkier analogues, such as MTMSA-TRP and MTMSATRP-TRP, were less cytotoxic (i.e., higher GI50) in RKO-pIRES cells, which was
consistent with their higher molecular weight. This is likely the result of decreased
diffusion. Further, MTMSA analogues had similar GI50 across the cell lines, which is
consistent with their decreased ionization. In contrast, MTMox analogs appear to be
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somewhat more cytotoxic in OATP expressing cell lines (Table 2.11), which is
consistent with their lower pKa and higher degree of ionization at pH 7.4 (Table 2.5).
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Table 2.10. Cytotoxicity of select MTMSA analogues in cells expressing OATP transporters.
Compound

MTM
MTMSA-PHE
MTMSA-TRP
MTMSA-PHE-TRP
MTMSA-TRP-TRP

RKO-pIRES
GI50
CI (95%)
(nM)
18.53 11.57 - 29.62
30.22 14.7 - 60.11
23.5 11.84 - 44.98
62.95 29.71 - 129.4
48.45
wide

RKO-OATP1B1
GI50
(nM)
3.53
17.56
16.29
33.23
41.25

RKO-OATP1B3

CI (95%)

p-value

0.19 - 9.5
10.39 - 28.96
6.15 - 39.91
12.95 - 76.94
22.73 - 68.58

0.9433
0.9591
0.9865
0.8004
0.9865

GI50
(nM)
5.09
22.08
22.32
124.6
29.51

CI (95%)

p-value

3.73 - 12.98
11.28 - 42.13
11.44 - 42.31
81.77 - 188.4
10.26 - 50.53

0.9681
0.9828
0.9996
0.4202
0.9116

Statistical comparisons were by two-way ANOVA vs. the RKO-pIRES cell line with adjustment for multiple comparisons.
Table 2.11. Cytotoxicity of select MTMox analogues in cells expressing OATP transporters.
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Compound

MTM^

RKO-pIRES
GI50
(nM)
18.53
23.72
780.9
1693
971.2

CI (95%)
11.57 - 29.62
18.11 - 30.91
538 - 1143
1075 - 2718
777 - 1277

RKO-OATP1B1
GI50
(nM)
3.53
15.01
94.90
117.8
128.5

RKO-OATP1B3

CI (95%)

p-value

0.19 - 9.5
1.5 - 18.1
73 - 115
103 - 139
107 - 159

0.9933
0.9977
0.0011
<0.0001
0.0002

GI50
(nM)
7.36
25.06
210
285.3
265

CI (95%)

p-value

3.73 - 12.98
23.04 - 27.11
192 - 230
261 - 310
231 - 301

0.9963
>0.9999
0.0047
<0.0001
0.0008

MTMox17
MTMox20
MTMox23
MTMox24
^MTM results are the same as in Table 2.10 and are included here for ease of comparison., Statistical comparisons were by twoway ANOVA vs. the RKO-pIRES cell line with adjustment for multiple comparisons.

In vivo pharmacokinetics of MTM and MTMSA-TRP-TRP in mice pre-treated
with rifampicin
Preliminary in vitro studies demonstrated that the pKa of MTM is ~4.9,
this observed pKa was significantly lower compared to analogues with amino acid
substitutions. Based on this, it was hypothesized that differences in pKa at physiological
pH would result in differences in transport by OATP transporters. MTM also has a
plasma half-life of under 5 hours compared to its analogue MTMSA-TRP-TRP, which
has a plasma half-life of over 18 hours. Therefore, to assess whether Oatp was important
for the clearance and biodistribution of MTM and its analogues, we used female FVB/N
wildtype and Oatp1a/1b knockout (Del(Slco1b2-Slco1a5)) mice to test this hypothesis in
vivo. A pharmacokinetic study of MTM or MTMSA-TRP-TRP with and without pretreatment of rifampicin was conducted in mice. Female FVB/N wildtype and Oatp1a/1b
knockout (Del(Slco1b2-Slco1a5)) mice were obtained and were given rifampicin (20
mg/kg) by oral gavage 1 hour prior to being given MTM (0.3 mg/kg) or MTMSA-TRPTRP (0.3 mg/kg) intravenously. The objective was to demonstrate differences in
clearance of MTM and analogue in the presence of an OATP inhibitor. Figure 2.6 and
Figure 2.7 Results in Table 2.12. demonstrated extended exposure of MTM as opposed
to that of its analogue MTMSA-TRP-TRP, which is less ionized at physiological pH.

64

Plasma Concentration (ng/mL)

1000

100

WT
10

Oatp 1a/1b KO

1
0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

Time (h)

Plasma Concentration (ng/mL)

Figure 2.6. Pharmacokinetic profiles of FVB/N wildtype and FVB/N Oatp 1a/1b KO mice
after treatment with MTM (0.3 mg/kg IV).
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Figure 2.7. Pharmacokinetic profiles of FVB/N wildtype and FVB/N Oatp 1a/1b KO mice
after treatment with MTM (0.3 mg/kg IV). Pre-treatment of rifampicin (20 mg/kg PO) was
administered orally 1 hour prior to IV dose of MTM.
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Figure 2.8. Pharmacokinetic profiles of FVB/N wildtype and FVB/N Oatp 1a/1b KO mice
after treatment with MTMSA-TRP-TRP (0.3 mg/kg IV).

10000

1000

WT + Rifampicin
Oatp 1a/1b KO + Rifampicin

100
0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

Time (h)
Figure 2.9. Pharmacokinetic profiles of FVB/N wildtype and FVB/N Oatp 1a/1b KO mice
after treatment with MTMSA-TRP-TRP (0.3 mg/kg IV).Pre-treatment of rifampicin (20
mg/kg PO) was administered orally 1 hour prior to IV dose of MTM.
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Table 2.12. Systemic exposure of MTM and MTMSA-TRP-TRP in wildtype (WT) and transgenic FVB/N mice with OATP KO
Oatp1a/1b knockout (KO) (Del(Slco1b2-Slco1a5)). Mice were pre-treated with an oral dose of Rifampicin (20 mg/kg) 1 hour prior to
an IV bolus dose of MTM (0.3 mg/kg) or MTMSA-TRP-TRP (0.3 mg/kg). Pharmacokinetic parameters were generated from a noncompartmental analysis of plasma concentration time points. (HPLCMS/MS results analyzed by Dr. Markos Leggas).

MTM

Transgenic strain

MTMSA-TRP-TRP

Rifampicin
CL
V
CL
V
Exposure
Exposure
(mg/kg) 1hr
(AUCt=0→∞)* (mL/h/kg) (mL/kg) (AUCt=0→∞)* (mL/h/kg) (mL/kg)
pre-treatment
0
90
1515
1252
16636
18
69
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FVB/N wildtype
FVB/N
Del(Slco1b20
258
1162
1389
28791
10
69
Slco1a5)
FVB/N wildtype
20
548
548
1306
29500
10
59
FVB/N
Del(Slco1b220
582
516
1607
32039
9
50
Slco1a5)
* AUCt=0→∞ defined as area under the curve from time 0 to infinity. CL-Observed clearance. V-Observed volume of distribution.

Conclusion
OATP transporters are very active in the facilitated transport of their
substrates into the liver. OATP1B1, and OATP1B3 are primarily expressed in the human
liver and are important for the uptake and metabolism of ionized compounds into the
liver. Here we present evidence that OATP transporters have more affinity for MTM
than its analogues. This finding is primarily based on physiochemical properties of MTM
vs. analogues. The structural modifications made to MTM are on the C3 side chain and
therefore do not interfere with the aromatic three ring core of the molecule. Preliminary
data demonstrates that the addition of large hydrophobic amino acids such as tryptophan,
ensures a more selectively active MTM analogue. In estimating the pKa of MTM and
analogues we observed an increase in pKa as these substitutions were added. The
differences observed in pKa reflect buffer access to the ionizable aromatic core of the
molecule. Analogues such as MTMox24 with a pKa of 6.8 and MTMSA-TRP-TRP have a
di-peptide TRP at their C3 side chain. Once buffer is added and fluorescence is read
these bulky side groups shield the fluorescent core of the molecule from ionization,
shifting the pKa. Initially it was reported that MTM has a pKa of 5 and in these studies, it
was estimated to be 4.9 [156-160]. At physiological pH MTM is 99% ionized, leaving a
very small fraction of unionized MTM in the plasma to be up taken by transporters. In
contrast, MTMSA-TRP-TRP with a pKa of 6.7 is only 32% ionized at physiological pH.
This reduction in ionizable fraction allows for more compound to circulate in the plasma
resulting in a higher plasma half-life for this analogue. Also, because there is more drug
circulating there is a better chance that drug will reach tumor tissue and cause a reduction
in tumor growth.
68

We also demonstrated that MTM competes for entry into OATP
transporters by conducting a competitive inhibition assay. The potent pan OATP
inhibitor, rifampicin was used in this assay. Rifampicin is an antibiotic normally used for
the treatment of tuberculosis, in this assay OATP expressing cell lines were co treated
with rifampicin, MTM or analogue and the uptake of the fluorescent OATP substrate 8FcA was measured. We observed that MTM analogues with a higher pKa were
competing less for entry via OATP transporters with 8-FcA in buffer that was pH 6 and
at pH 7.4. This result supports the hypothesis that OATP transporters have more apparent
affinity for MTM because of its physiochemical properties. Cell viability studies were
conducted in OATP expressing cells to demonstrate overall entry into the cells over a
period of 72 hours. These results showed that MTM analogues were less toxic than
MTM in the control cell line. And because MTM is ionized to a greater extent, it will
enter the cell in higher concentrations than its analogues. An apparent shift in the GI50 is
demonstrated in cell lines expressing OATP.
Based on in vitro studies we hypothesized that these OATP transporters
play a mechanistic role in the increase in systemic exposure of MTM analogues.
Wildtype FVB/N and transgenic FVB/N Oatp1a/1b knockout (Del(Slco1b2-Slco1a5))
mice were pre-treated for 1 hour with rifampicin and in Table 2.12 we report differences
in exposure, clearance and volume of distribution. These results reveal that MTM is
entering the liver at higher concentrations than its analogues. There also may be other
isoforms of Oatp playing a part in the clearance of MTM. Mice do not express a direct
homolog of OATP1B1 and OATP1B3, in contrast, they express Oatp1b2 which is
primarily expressed in mouse liver and is homologous with hOATP1B1 and 1B3. Other
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mouse homologs of Oatp could possibly be compensating in the presence of the
inhibitor, rifampicin. Furthermore, these findings will impact the development of new
MTM analogues by suggesting development of analogues that are less ionized. Allowing
them to reside in circulation for longer periods of time resulting in more distribution and
tumor targeting.
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CHAPTER 3. MTM ANALOGUES DISPLACE AND PHYSICALLY INTERACT
WITH ETS PROTEIN BINDING IN EWING SARCOMA
Introduction
In oncology there have been challenges discovering effective treatments
for cancers involving aberrant transcription factors. These oncogenic transcription factors
have been deemed “undruggable “due to their lack of an accessible binding pocket for
small molecules. Ewing sarcoma is the second most common bone malignancy in
children and adolescents. Ewing sarcoma is characterized by a chromosomal
rearrangement that fuses the transactivation domain of the RNA binding protein, EWS,
with the DNA binding domain of an ETS protein. In more than 85% of Ewing sarcoma
cases this translocation involves the ETS family member FLI1, ERG, also an ETS family
member is seen in 10-15% of Ewing sarcoma cases [24]. EWS-FLI1 acts as a
transcriptional activator and repressor in Ewing sarcoma. Ewing sarcoma cells have also
been shown to be extremely dependent on EWS-FLI1 activity for viability and growth,
making the transcription factor a desirable target for treatment [161]. Additionally,
Ewing sarcoma tumors possess very low mutation rates, harboring very few mutations
other than EWS-ETS gene rearrangements [65, 66].
One approach to treating Ewing sarcoma family of tumors (ESFT) is to
directly target transcriptional activators of the disease. In 2011, a high throughput drug
screen was conducted to find inhibitors of EWS-FLI1. After testing over 50,000
compounds mithramycin was shown to be the most potent inhibitor of EWS-FLI1
activity. Mithramycin was also shown to down regulate EWS-FLI1 target genes and
decrease tumor volume in xenograft studies [118].
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Mithramycin is a tricyclic polyketide that was originally isolated from
Streptomyces Argillaceous for its antibiotic properties but was soon shown to have more
potent antitumor effects [119]. Mithramycin binds DNA in the minor groove at G/C rich
regions in a non-intercalative manner in the presence of cations, mainly Mg2+ as a
coordinated dimer [162]. This binding prevents transcription factor activity at promoter
regions. Despite the biological activity its use as an anticancer agent is limited by severe
adverse effects[121]. In 2016 a phase I/II study of mithramycin in children and adults
with refractory Ewing Sarcoma was conducted. Outcomes from this study showed
elevated serum transaminase levels during treatment [120]. Dose limiting hepatotoxicity
is a characteristic of treatment with mithramycin and could be a result of mithramycin
inhibition of the Sp1 transcription factor. Sp1 is a transcription factor that binds GC rich
regions of many promoters and is involved in many processes including cell growth
[163, 164], apoptosis [163], immune responses [165], response to DNA damage,
chromatin remodeling and cell differentiation [166]. Due to the associated toxicities of
mithramycin the development of less toxic and more selective analogues of mithramycin
is of great interest. Here we sought to identify and develop analogues that preferentially
target EWS-ETS over Sp1.

Materials and methods
Cell Lines and reagents
RPMI-1640 (Sigma, St. Louis, MO), DMEM (Sigma, St. Louis, MO)
media were prepared with 10% v/v heat-inactivated fetal bovine serum (FBS) (Atlanta
Biologicals, Flowery Branch, GA) and 1% v/v 10,000 units/mL penicillin and 10,000

72

μg/mL streptomycin (PS) (Life Technologies, Carlsbad, CA). All media were prepared
with 1.5−2 g/L sodium bicarbonate (Sigma, St. Louis, MO), pH was adjusted to 7.2, and
filtered with 0.2 μm filters (Corning, Corning, NY) prior to use. TC-32 (RPMI-1640) cell
line (culture medium) were gifts from Dr. Timothy Cripe (Hospital Research Foundation,
Columbus, OH). PC-3 (RPMI-1640) and A549 (DMEM) cell lines were obtained from
ATCC (Manassas, VA).
Molecular subcloning and isolation of Sp1
Sp1 was cloned and isolated for its use in TR-FRET assays. Sp1 cDNA
was cloned into a pOTB7 bacterial plasmid vector (Harvard Medical school plasmid
depository). The plasmid was amplified by growing bacteria in LB media (VWR,
Radnor, PA) supplemented with chloramphenicol (25 µg/ml) (VWR, Radnor, PA), the
plasmid was then isolated from bacteria cells using the QIAGEN plasmid kit (QIAGEN,
Hilden, Germany). Full length pOTB7-Sp1 plasmid was then digested with EcoRI and
XhoI (New England Biolabs, Ipswich, MA). Simultaneously, a pET28 expression vector
was also digested with EcoRI and XhoI (New England Biolabs, Ipswich, MA). Digestion
products from both vectors were run on a 1% agarose gel, then isolated via gel
purification using the GeneJET gel extraction kit (Thermo Fisher Scientific, Waltham,
MA). The target amplicon (Sp1) was then ligated into the pET28a expression vector
using T4 DNA ligase (Thermo Fisher Scientific, Waltham, MA). Chemically competent
One Shot TOP10 (Thermo Fisher Scientific, Waltham, MA) E. coli cells were used to
propagate vectors under kanamycin (100 µg/mL) (VWR, Radnor, PA) selection (Thermo
Fisher Scientific, Waltham, MA). The resulting vector was extracted and purified using
the GeneJET plasmid prep kit (Thermo Fisher Scientific, Waltham, MA). The resulting
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plasmid was then transformed into BL21(DE3) cells (New England Biolabs, Ipswich,
MA). Transformed BL21(DE3) cells were grown in LB media supplemented with
kanamycin (100 µg/ml) and after 8 hours of shaking incubation at 37˚C media was
supplemented with isopropylthio-β-galactosidase (IPTG) (400 µM) to induce protein
expression for 4 hours. After induction cells were spun down and HIS- tagged Sp1 was
isolated using the HisPur Ni-NTA spin purification kit (Thermo Fisher Scientific,
Waltham, MA). HIS-tagged Sp1 protein was validated by western blot (All plasmid map
sequences referenced in APPENDIX 1.
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Validation of ERG and Sp1 DNA binding
HIS-tagged ERG DNA binding domain (DBD) was obtained from Dr.
Oleg Tsodikov. It was expressed in a pET28 vector and upon obtaining an aliquot
electrophoretic mobility shift assay (EMSA) was conducted to validate DNA: protein
binding. EMSA binding buffer (5X) consisted of 100 mM HEPES (pH 7.2), 160 mM
KCl, 0.5 mM EDTA (pH 8), 50% Glycerol, 350 ng/µl BSA, 40 ng/µl poly(dI-dC), 12.5
mM DTT 5%. Binding buffer, ERG-DBD or Sp1 (1 µM) and dsDNA probes (ETSforward: 5’-CGTATGGAAGGAAGGAAGGAA GGAAGGAAT CACT-3’reverse: 5’AGTGATTCCTTCCTTCCTTCCTTCCTTC CATACG-3’) (Sp1-forward: 5’CGTATGGGCGGGGGCGGGGGCGGGTCACT-3’ reverse: 5’AGTGACCCGCCCCCGCCCCCGCCCATACG) were combined in a micro centrifuge
tube and incubated on ice for 20 minutes. Prior to incubation 5% native precast MiniPROTEAN TBE gels (Bio-Rad, Hercules, CA) were submerged in TBE running buffer
(Tris base 1 M, Boric acid 1 M, EDTA 0.02 M) and were allowed to pre-run at 50 V for
1 hour at 4˚C. Samples were loaded into each well (20 µl) and gel was run at 45 V (4˚C)
until loading dye front ran to the bottom of the gel. Gels were then removed from the gel
electrophoresis apparatus and incubated in SYBR safe (Edvotek, Washington D.C.)
following the manufacturer’s directions for 15 minutes. Images of gels were taken on a
ChemiDoc MP (Bio-Rad, Hercules, CA).
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Time resolved fluorescence resonance energy transfer (TR-FRET).
TR-FRET assays were performed in 384-well black low volume plates
(Greiner Bio-One, Kremsmunster, Austria) with a total working volume of 20 µL. Histagged ERG or recombinant His-tagged Sp1 (10 nM) was added to the reaction buffer
containing 4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 125 mM NaCl, 10
mM Tris - HCl (pH 7.4), 0.2% Tween-20. Cal635-labeled oligonucleotides (100 nM) and
mouse monoclonal LANCE® europium labeled anti-6xHis antibody (Perkin Elmer,
Waltham, PA) (5 nM) were added to the reaction mixture. The plate was then incubated
at 4°C for 1 hour. MTM compounds were then added at half-log concentrations (0 nm, 3
nm-10 µM) and the plate was once again incubated for 1 hour at 4°C shielded from light.
Plates were read on a BioTek Synergy H1 plate reader (BioTek, Winooski, VT)
instrument with excitation set to 325 nm and emission read at 618 nm (to read EU
emission) and 644 nm (to read Cal635 FRET emission) after a delay of 50 µsec and a
total integrated read time of 400 µsec. The equation 𝐹𝐴 /(𝐹𝐴 + 𝐹𝐷 ) where FA is the
fluorescent signal from the FRET acceptor and FD is the fluorescent signal from the
FRET donor was used to calculate the ratio of the 618 nm and 644 nm readings was used
to assess the degree of FRET, which is proportional to the amount of total binding. The
ratio from a control sample containing no protein was subtracted from the data and the
binding curves plotted relative to total drug concentration. Curve fitting was performed
using GraphPad Prism 8.0 software (GraphPad Software, La Jolla, CA). The optimal
conditions were determined to be 100 nM oligonucleotide and 30nM ERG, 10 nM Sp1.
Negative inhibitor control consisted of 100 nM of oligonucleotide that lacked Sp1 and
ERG binding sites.
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Cellular thermal shift assay (CETSA)
TC-32 cells were expanded and seeded in T75 flasks (~2 million cells/ml)
and treated with DMSO (Sigma, St. Louis, MO), (10 µM) MTM or MTM analogue for 3
hours at 37 °C. Cells were then trypsinized, counted and centrifuged at 300 g for 3
minutes at room temperature to the pellet cells. Cell culture medium was carefully
discarded, and cells were then resuspended in PBS (Sigma, St. Louis, MO) supplemented
with protease inhibitors. Cells were then distributed into 10 or 11 different aliquots in
0.2-ml PCR tubes (VWR, Radnor, PA) with 100 μl of cell suspension in each tube (~3
million cells per tube). Each tube was designated to be heated to a certain temperature
(37 - 67 °C). The tubes are kept at room temperature before the heat treatment step. PCRtube strips were heated to their designated temperature using a 96-well thermal cycler for
3 minutes each. Immediately after heating, tubes were removed and incubated at room
temperature for 3 minutes to cool. Immediately after cooling tubes were snap frozen in
liquid nitrogen and stored at -80˚C overnight. Cell lysis was completed by twice using
liquid nitrogen and a thermal cycler set at 25˚C to freeze thaw cell suspensions. Cell
suspensions were then vortexed briefly and cell lysate containing tubes were centrifuged
at 20,000 g for 20 minutes at 4˚C to pellet cell debris. Supernatant (90 µL) containing the
soluble protein fraction was transferred to a new tube and used for western blot analysis
using traditional western blot analysis, as described above, as well as simple
western[167].
Western blot analysis.
TC-32 cells were treated as described in section 3.2.4. After incubation,
cells were rinsed with cold PBS (Sigma, St. Louis, MO) and harvested using a cell
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scraper in RIPA lysis buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40,
1% sodium deoxycholate, and 0.1% SDS) with 1× protease and phosphatase inhibitors
(Thermo Fisher Scientific, Waltham, MA) . Then, for each sample, 15 µg of protein
lysate was loaded onto Mini-PROTEAN TGX pre-cast 4– 15% polyacrylamide gels
(Bio-Rad, Hercules, CA) and electrophoretically separated using 1× SDS PAGE running
buffer. The proteins were then transferred to a nitrocellulose membrane by using a TransBlot turbo Gel Transfer Device (Bio-Rad, Hercules, CA). The membranes were blocked
with 5% NFDM for 1 hour then probed with rabbit monoclonal antibodies against β-actin
(ab115777; Abcam, Cambridge, MA ), Fli-1 (sc-365294; Santa Cruz, Dallas, TX), Sp1
(A303-944A; Bethyl Laboratories, Montgomery, TX) and Total RNAPII (A300-653A;
Bethyl Laboratories, Montgomery, TX). This step was followed by incubation with a
secondary anti- rabbit IgG HRP-linked antibody (7074S; Cell Signaling technology,
Danvers, MA), and protein bands were visualized with a Chemidoc MP imager (BioRad, Hercules, CA).
Simple western analysis of CETSA samples
Following the CETSA protocol total protein concentrations were
determined using the Pierce Micro BCA Protein Assay Kit (Thermo Fisher Scientific,
Waltham, MA). A capillary-based western blotting system (ProteinSimple Wes, San
Jose, CA) was used to assess protein expression. All procedures were completed
according to the manufacturer’s instructions and default settings. The concentration of all
protein lysates was 0.4mg/ml, antibodies used in experiments Fli-1 (sc-365294; Santa
Cruz, Dallas, TX) and Vinculin (MCA465GA; Bio-Rad, Hercules, CA) were diluted in
antibody dilution buffer at 1:50 and 1:500 respectively. The anti-mouse secondary
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antibodies included in the Wes Detection Module kit (ProteinSimple Wes, San Jose, CA)
were used. All data were analyzed with the Compass Software associated with the Wes
instrument. Bands were quantified using GelQuant.net software provided by
biochemlabsolutions.com. Data was then normalized by dividing each temperature by the
relative band intensity at the lowest temperature. Relative band intensities were then
exported to GraphPad Prism 8.0 (La Jolla, CA) and plotted against their temperatures
and a Tagg was estimated for each compound.

Results and Discussion
To assess the relative capacity of MTM and MTM analogues to interfere
or interact with ETS and Sp1, we used a FRET biochemical assay. For the FRET assay
with ETS transcription factor we used ERG protein supplied by Dr. Hou and Dr.
Tsodikov. For the Sp1 FRET assay we first expressed and purified full-length protein.
Because ERG and FLI1 as well as all ETS transcription factors share the same DNA
binding domain (DBD) this was suitable to use to measure the interaction between ERG
and the ETS DBD.
Validation of recombinant Sp1 expression
The following cloning of Sp1was completed by cutting Sp1 out of the
p0TB7 vector using restriction enzymes. The insert was then ligated into the pET28a
expression vector where the gene was fused to a 6X HIS tag. The vector was then
transfected into BL21 (DE3) cells and expression of Sp1 was induced by adding IPTG to
the growth media. In Figure 3.1 Sp1 cloning into the pet28a expression vector was
validated by restriction enzyme digestion. After induction, total protein was extracted and
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6X HIS tagged Sp1 was isolated from BL21 (DE3) cells. Expression of 6X HIS tagged
Sp1 shown in Figure 3.2 and compared to other cell lines that also express Sp1.

SP1 insert

Figure 3.1. Validation of Sp1 ligation into pET28a expression vector. A 1% agarose gel
ran and stained with Sybr safe to confirm size of ligated plasmids. Six separate pET28aSp1 colonies were subjected to a restriction enzyme digest (lanes 2-7). This was compared
to the pET28a empty vector (lane 8) and p0TB7-Sp1 restriction digest (lane 9) the original
source of the Sp1 insert.
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Figure 3.2. Validation of isolated 6X HIS-tagged Sp1 from BL21 (DE3) cells. Western blot
analysis of TC-32 (Ewing, lanes 2 and 3), 5838 (Ewing, lanes 4 and 5) and PC3 (prostate
cancer, lanes 6 and 7) cells, 6X HIS-tagged Sp1 (1 µg, 3 µg lanes 8 and 9).
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Validation of ERG and Sp1 binding to relative consensus sequences
6X HIS tagged ERG and 6X HIS-tagged Sp1 was expressed and isolated
for use in TR-FRET assays. In the TR-FRET assays the protein of interest must bind to
its DNA consensus site. To confirm 6X HIS-tagged ERG and 6X HIS tagged Sp1
binding to DNA an electrophoretic mobility shift assay (EMSA) was conducted. In
Figure 3.3 a 34bp oligomer with an ETS microsatellite binding site was combined with
increasing concentrations of 6X HIS-tagged ERG. As the concentration of 6X HIStagged ERG was increased there is apparent binding of the peptide to the DNA as shown
by a shift in the molecular weight of the bands in the gel. As the concentration of protein
increases there is more protein bound to the DNA. In Figure 3.4 a 34bp oligomer with
Sp1 binding sites was combined with purified 6X HIS-tagged Sp1. As the concentration
of 6X HIS-tagged Sp1is increased the oligomer is more occupied by protein increasing
its molecular weight as shown by a drastic shift in the DNA.
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Figure 3.3. 6X HIS tagged ERG binds ETS microsatellite. Validation of 6X HIS tagged
ERG bound to DNA probe by EMSA, 0 nM, 10 nM, 30 nM, 100 nM, 300 nM and 500 nM
6X HIS tagged ERG was combined with an oligomer expressing an ETS microsatellite
(100nM) and a shift in the molecular weight of the DNA was observed.
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Figure 3.4. 6X HIS tagged Sp1 binds Sp1 DNA promoter site. Validation of 6X HIS tagged
Sp1 bound to DNA probe by EMSA, 0 nM, 10 nM, 30 nM, 100 nM, 300 nM and 500 nM
6X HIS tagged Sp1 was combined with an oligomer expressing an Sp1 promoter site
(100nM) and a shift in the molecular weight of the DNA was observed.
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MTM and analogues displace the ERG DBD more potently than the Sp1 DBD
Having demonstrated that protein constructs 6X HIS tagged ERG and 6X
HIS tagged Sp1 bind ETS and Sp1 DNA binding domains (Figure 3.3 and Figure
3.4Error! Reference source not found.), we then conducted a TR-FRET assay. This assay
was used to quantitatively measure concentrations of MTM or MTM analogue required
to decrease TR-FRET activity, thereby disrupting 6X HIS tagged ERG and 6X HIStagged Sp1 binding to their respective DNA oligomers. This assay was used as a tool to
screen for MTM analogues that more selectively displaced ETS binding. Figure 3.5 and
Figure 3.6 depict TR-FRET reaction with and without drug respectively. As described
above in the methods MTM or analogue was added to the reaction in a concentration
dependent manner and the TR-FRET ratio was measured. The data was then fit using a
non-linear regression to estimate an EC50 for each analogue. MTM and analogues were
tested in this assay and as hydrophobic substitutions were added to the C3 side chain of
MTM there is an increase in the ERG and Sp1 DBD EC50 values. This result suggests
that MTM analogues are displacing DNA bound ERG. This displacement happens at
lower concentrations as C3 substitution increases in hydrophobicity and aromaticity. The
ratio of ERG displacement to that of Sp1 displacement was calculated (Table 3.1) and
analogues that are more specifically targeting the ERG-DBD over the Sp1-DBD have a
higher ratio. In some cases, there was a minimal effect at which MTM analogues
displaced the peptides, therefore the AUC was also estimated for each analogue as a
more representative measure and a better way to assess the relative difference between
ERG and Sp1.
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Figure 3.5. FRET reaction when no drug is present. Energy from the EU-labeled Anti-His
antibody is transferred to the CAL635 labeled DNA oligo because the fluorophores are in
close proximity to one another.

Figure 3.6. FRET reaction when drug is present. MTM or analogue present at increasing
concentrations displaces ERG: DNA binding. Energy from the EU-labeled Anti-His
antibody is not transferred to the CAL635 labeled DNA oligo because the fluorophores are
no longer in close proximity to one another.
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Table 3.1. Estimated EC50 of MTM and select analogues assessing their capacity to interfere with DNA binding of ERG and Sp1
using the TR-FRET assay.
MTM analogue

ERG
EC50

CI (95%)

Sp1 EC50

CI (95%)

MTM

26.46

21.22 - 33.07

121.5

MTMSA-PHE

51.01

36.75 - 71.56

MTMSA-TRP

62.31

MTMSA-PHE-TRP
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wide

AUC
(ERG)
1563

AUC
(Sp1)
9252

EC50
ratio
4.59

AUC
ratio
5.92

332.4

wide

2107

9323

6.52

4.42

46.90 - 83.35

261.9

226.5 - 301.6

2000

9499

4.20

4.75

187

142.3 - 246.6

519

402.1 - 705.4

2588

9902

2.78

3.83

MTMSA-TRP-TRP

112

68.73 - 181.1

1788

1514 - 2055

2794

10612

15.96

3.80

MTMox17

148.2

111 - 204.6

49.8

47.67 - 53.65

10912

9574

0.34

0.88

MTMox18

510.3

wide

2307

1574 - 4501

11851

11191

4.52

0.94

MTMox19

16.05

wide

105.3

99.9 - 112.4

11606

9536

6.56

0.82

MTMox20

97.68

wide

1001

790.2 - 1278

11769

10061

10.25

0.85

MTMox23

110.1

24.01 - 1818

554.8

423.5 - 708.3

10334

10463

5.04

1.01

MTMox24

133.9

105.6 - 170

1706

1455 - 1922

1622

10289

12.74

6.34

MTM analogues physically interact with EWS-FLI1
Targeted engagement is vastly important when developing a targeted
therapy. For an ideal targeted therapy, target engagement should be optimal in specific
cells and tissues and minimal in other cells and tissues. In Ewing sarcoma EWS-FLI1 is
the main driver of oncogenesis and inhibiting its activity is of great interest. Here we
used CETSA assays to determine if MTM or analogue binding affects protein stability
[167]. Thermally induced unfolding experiments give way to protein melting curves.
These melting curves usually shift to a higher temperature when the protein is drug
bound suggesting protein stability. We also sought to understand physical interactions
between MTM analogues and EWS-FLI1. Upon completion of the experiment relative
band intensities were measured, normalized, and plotted against the temperature to
generate Tagg (the temperature at which a majority of the unliganded protein has
denatured and aggregated) for each analogue. In these studies, it is suggested that drug
bound MTM and analogues differentially stabilize and physically interact with the EWSFLI1 protein. In Figure 3.7 this is shown by the expression of EWS-FLI1 at higher
temperatures where it would have otherwise been degraded. To relate CETSA results
from Figure 3.7 to target occupancy, we performed a dose response measurement
conducted at a constant temperature: the isothermal dose-response fingerprint
(ITDRFCETSA) Figure 3.8. This assay was used to measure concentration-dependent
target engagement. We expected that the IDTRFCETSA values would correlate with IC50
values previously collected, however that is not reflected in this result.
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DMSO

Tagg: 44.4˚C

MTM

Tagg: 49.8˚C

MTMSA-PHE

Tagg: 51.5˚C

MTMSA-TRP

Tagg: 54.1˚C

MTMSA-TRP-TRP

Tagg: 52.2˚C

MTMox24

Tagg: 58.4˚C

Figure 3.7. CETSA demonstrating MTM analogue interaction with EWS-FLI1. TC-32 cells treated with DMSO (0.01%), or MTM
analogues (10 µM). EWS-FLI1 (~68 kDa) was probed using the Simple Wes equipment. Each blot is representative experiment from 3
biological replicates with each analogue.
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Figure 3.8. ITDRFCETSA determination of MTM and select analogues by western blot analyses. TC-32 cells treated in dose response
manner (half log concentrations 0 nM-10µM) with MTM (A), MTMSA-PHE (B), MTMSA-TRP (C), MTMSA-TRP-TRP (D),
MTMox23 (E), MTMox24 (F) and heated at each associated Tagg (blue triangles represent an increase in the dose). EWS-FLI1 (~68 kDa)
was probed using the traditional western blotting method. Β-actin (~ 42kDa) was used as a loading control and was also probed using
traditional western blotting methods. Bands were quantified and relative intensities were plotted against MTM or analogue
concentration. Non-linear regression was used to determine EC50 values for each analogue. This is a representative experiment from 3
biological replicates.
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Conclusion
This work is one of the first studies to more comprehensively examine
how MTM and analogues bind DNA and interact with EWS-FLI1. In biochemical
experiments we demonstrated that MTM and analogues interact with the ETS DBD ERG
more potently than they do with Sp1. We also demonstrated that MTM and analogues
physically interact with EWS-FLI1, possibly stabilizing the protein, in intact cells. MTM
binds DNA and exerts its inhibitory activity by interacting with transcription factors. It
has also been proposed that MTM analogues with amino acid additions to the C3 side
can stabilize EWS-FLI1 [2]. Here we present evidence that MTM analogues with
substitutions like tryptophan physically interact with EWS-FLI1, thereby affecting
transcription and the integrity of the DNA
MTM binds DNA and exerts its inhibitory activity by interacting with
transcription factors at GC repeats. It has also been proposed that MTM analogues with
amino acid additions to the C3 side can stabilize EWS-FLI1. Structural modifications
made to the side chain of MTM demonstrate differences in the displacement of ERG and
Sp1. MTM analogues MTMSA-TRP-TRP and MTM24 both displace ERG binding more
than Sp1.
Identifying an MTM analogue that could modulate EWS-FLI1 function
by physically interaction was also of great interest. To better understand MTM: EWSFLI1target engagement we conducted CETSA experiments. This assay is based on the
premise that upon heating EWS-FLI1 will unfold and aggregate at a certain temperature.
We hypothesized that this heat induced aggregation would be disrupted by the addition
of MTM or its analogues. Ultimately, we demonstrated that MTM analogues with amino
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acid substitutions to the C3 side chain of MTM stabilize the EWS-FLI1 transcription
factor at higher temperatures than MTM. Intact TC-32 cells treated with DMSO and
MTM had a Tagg of 44.4°C and 49.8°C respectively, and as amino acid substitutions were
added the Tagg increased. MTM analogues with dipeptide substitutions had the highest
Tagg thereby displaying the strongest physical interaction between EWS-FLI1 and
analogue. This result coincides with the TR-FRET results, demonstrating that MTM
analogues with large hydrophobic amino acid additions to the C3 side chain are
interacting with EWS-FLI1.
Isothermal dose-response fingerprint CETSA (ITDRFCETSA) assays were
conducted to identify stabilization of EWS-FLI1 as a function of increasing MTM or
analogue concentration while applying a heat challenge at the previously determined Tagg
[167]. In this assay we probed for protein expression of EWS-FLI1 and results
demonstrated that MTM analogues engage the target protein, EWS-FLI1, more potently
than MTM. This result is important because it shows that not only are these analogues
physically interacting with EWS-FLI1, this interaction is also stronger, requiring less
drug to elicit an effect.
CETSA studies were also conducted to demonstrate a physical interaction
between Sp1 and MTM analogues. However, no relevant change in the Tagg was observed
after probing for Sp1 in Error! Reference source not found.. This result was puzzling, s
o we then designed another CETSA assay where we increased the temperatures at which
the intact cells were subjected to. This resulted in similar results, no apparent change in
the expression of Sp1 upon increasing the temperatures was seen in Error! Reference
source not found.. This result may be able to be explained in future studies by making
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changes to the CETSA protocol, testing treated cell lysates in addition to intact cells and
comparing the results. Overall, there are distinct differences in the way MTM and MTM
analogues interact with EWS-FLI1 and Sp1. At the biochemical level we showed an
interaction for both and both were displaced. However, in a whole
cell system, we were unable to demonstrate that a physical interaction with Sp1 was
detectable using the CETSA assay. Together these findings demonstrate the importance
of developing an MTM analogue that can directly target EWS-FLI1 binding sites without
perturbing other important transcription factors like Sp1.
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CHAPTER 4. OLAPARIB SENSITIZES EWS-FLI1 TO MTM AND ANALOGUE
TREATMENT
Introduction
EWS-FLI1, being the main driver of oncogenesis in Ewing sarcoma is the
most important target for its treatment. However, there are challenges when attempting to
target a transcription factor with a small molecule. Alternatively, many researchers have
sought out transcriptional partners of EWS-FLI1 that may aid in inhibiting EWS-FLI1
activity. In many cases protein-protein interaction partners of EWS-FLI1 are targeted
[168].
RNA helicase A (RHA) has been identified as a transcriptional protein
partner of EWS-FLI1 [44]. RHA is a DNA/RNA helicase that is involved in many
essential processes including RNA metabolism and transcription [169, 170]. RHA was
found present at consensus sites occupied by EWS-FLI1 and it was required for
malignant transformation of fibroblasts [44]. Reports also demonstrated that after
inhibiting RHA-EWS-FLI1 binding EWS-FLI1 activity was reduced [44].
Another transcriptional partner of EWS-FLI1 is RNA polymerase II
(RNAPII) [168]. RNAPII is a 12-subunit complex that is the synthetic apparatus of
mRNA [171]. The Rpb7 subunit was shown to directly bind to the EWS portion of EWSFLI1, suggesting that EWS-FLI1 interaction with RNAPII could modulate EWS-FLI1
expression of its target genes [115]. The carboxyl terminal domain (CTD) of RNAPII is
the largest subunit and it is essential for cell survival [171]. The CTD domain of RNAPII
is highly conserved across fungi, plants and animals and consists of 25-52 tandem
repeats of the heptad Y1S2P3T4S5P6S7 [171]. When the cell is undergoing transcription
RNAPII is hyperphosphorylated. This phosphorylation is carried out by cyclin dependent
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kinases (CDK), a family of kinases known for their role in regulating the cell cycle.
CDKs are also involved in transcription, mRNA processing and DNA damage repair
[172]. Iniguez et al, demonstrated that cell lines expressing EWS-FLI1 are specifically
sensitive to CDK12 inhibition [85]. Using a small molecule CDK12/13 inhibitor, THZ1,
they also demonstrated synthetic lethality with EWS-FLI1. Additionally, they showed
that the DNA damage repair mechanisms in EWS-FLI1 expressing cell lines was
impaired by CDK12 inhibition, and with the combination of Poly (ADP-ribose)
polymerase 1 (PARP1) inhibitors they saw synergistic reductions in tumor growth and an
extension of survival in Ewing sarcoma mouse models [85]. CDK12 is responsible for
recruiting many DDR proteins to the site of a lesion that are active in homologous
recombination (HR) [173]. HR consist s of a series of pathways that function in the
repair of single and double stranded breaks [174]. DNA repair genes BRCA2, FANC1
and FANCD2 are are active in HR and carry more intronic polyadenylation sites than
other expressed genes. When CDK12 activity is inhibited their usage to repair damaged
DNA in the cell becomes cumulative, demonstrating unusual sensitivities to CDK12 loss
[175]. The inhibition of CDK12, inhibitors like THZ1 demonstrated a gene-lengthdependent elongation defect. This defect lead to a shortening of transcripts by premature
termination in genes with a high number of polyadenylation sites, especially in DNA
repair and core DNA replication genes [172].
MTM and analogues target EWS-FLI1 and the basic transcriptional
machinery in Ewing sarcoma cells. There is also evidence that EWS-FLI1 expressing
cell lines overexpress PARP1 and are sensitive to PARP1 inhibition [85, 112, 176].
PARP proteins are a family of 18 enzymes that are involved in many essential cellular
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functions including transcription, DNA damage response, genomic stability maintenance,
cell cycle regulation and cell death [177]. These enzymes share the ability to catalyze the
transfer of ADP-ribose to target proteins [178, 179].
Skidmore et al, provided evidence that PARP1 activity is increased as a
response to DNA damaging agents and radiation, there has also been extensive evidence
that accumulation of lesions in DNA has causes an increase in PARP1 levels [180, 181].
PARP1 is involved in base excision repair (BER) in response to single stranded DNA
breaks and is also a component of the BER complex including, DNA ligase III, DNA
polymerase β, and the XRCC1 protein [182]. PARP1 specifically, has been shown to
play a role in nucleotide excision repair (NER) as well [183]. Flohr et al developed an
assay demonstrating that NER processes are reduced in the presence of a PARP1
inhibitor.
Because PARP1 plays a role in DNA damage repair, inhibition of this
enzyme can result in genomic instability and accumulation of cells with damaged DNA.
This also results in cell cycle arrest, and following DNA damage, cells require ADP
ribosylation to progress through the cell cycle [184, 185]. PARP11 has also been shown
to be a key component of the cell cycle G2 checkpoint, if inhibited also prevents cells
with damaged DNA from being able to enter mitosis [185]. Also, PARP1-/- deficient
mice are extremely sensitive to gamma radiation and DNA damaging agents have been
shown to cause rapid apoptosis in PARP1-/- cells. Lastly, PARP1-/- mice have been
shown to thrive suggesting that PARP1 functionality is relatively dispensable for normal
activity but is an essential survival factor for DNA damage [186].
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Brenner et. al. demonstrated that TMPRSS2-ERG, an ETS fusion gene in
prostate cancer, interacts with PARP11. They also demonstrated that PARP1i (PARP1
inhibitors) inhibit ETS positive prostate xenograft growth. Based on these results they
investigated ETS fusions in Ewing Sarcoma. Cell invasion assays demonstrated that
siRNAs against PARP11 and EWS reduced cell invasion, but knockdown of other key
DNA repair enzymes XRCC1, XRCC3 and XRCC4, had no effect. From this it was
concluded that PARP11 has a DNA repair independent role in Ewing sarcoma cell
migration. Finally, they showed that EWS-FLI1 maintains PARP1 mRNA expression
after knockdown experiments showed that EWS-FLI1 knockdown decreased PARP1
protein expression and promoter activity. Overall, their studies showed that an EWSFLI1:PARP1 positive feedback loop in transcriptional activation, together with the
potentiation of DNA damage by PARP1 as the two mechanisms contributing to PARP1.
Here, we sought to identify analogues of MTM that selectively perturb the
ETS transcription factor complex and afford efficacy in Ewing sarcoma as a
monotherapy and potentially in combination with olaparib, a PARP inhibitor. We
hypothesize that modifications to the side chain of MTM stabilize RNAPII and disrupt
transcription activity by causing DNA damage. DNA damage imparted on the cell will
be then potentiated with the addition of a PARP inhibitor.

Materials and Methods
Cell Lines
RPMI-1640 (Sigma, St. Louis, MO), media was prepared with 10% v/v
heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Flowery Branch, GA)
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and 1% v/v 10,000 units/mL penicillin and 10,000 μg/mL streptomycin (PS) (Life
Technologies, Carlsbad, CA). All media were prepared with 1.5−2 g/L sodium
bicarbonate (Sigma, St. Louis, MO), pH was adjusted to 7.2, and filtered with 0.2 μm
filters (Corning, Corning, NY) prior to use. TC-32 (RPMI-1640) cell line (culture
medium) were gifts from Dr. Timothy Cripe (Hospital Research Foundation, Columbus,
OH). PC-3 (RPMI-1640) cell lines were obtained from ATCC (Manassas, VA). A673
and TC-32 shEWS-FLI1 #6 cell lines were gifts from Dr. Kimberly Stegmaier (Harvard,
Dana-Farber Cancer Institute, Cambridge, MA). All cell lines were grown at 37 °C under
5% CO2 in a humid incubator and were tested regularly for mycoplasma using the
MycoAlert mycoplasma detection kit (Lonza, Basel, Switzerland). Drug stock solutions
were made in DMSO at 50 mM for olaparib and 10 mM for MTM and its analogues.
Drug stock solutions were stored at -20°C in the dark and diluted in culture medium
immediately before use.
Western blot analysis.
TC-32 and PC3 cells were treated with the respective chemical
compounds for 24 hours in 6-well plates. After incubation, cells were rinsed with cold
PBS (Sigma, St. Louis, MO) and harvested using a cell scraper in RIPA lysis buffer (25
mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, and
0.1% SDS) with 1× protease and phosphatase inhibitors (Thermo Fisher Scientific,
Waltham, MA) . Then, for each sample, 15 µg of protein lysate was loaded onto MiniPROTEAN TGX pre-cast 4– 15% polyacrylamide gels (Bio-Rad, Hercules, CA) and
electrophoretically separated using 1× SDS PAGE running buffer. The proteins were
then transferred to a nitrocellulose membrane by using a Trans-Blot turbo Gel Transfer
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Device (Bio-Rad, Hercules, CA). The membranes were blocked with 5% NFDM for 1
hour then probed with rabbit monoclonal antibodies against γ-H2A.X (ab81299; Abcam,
Cambridge, MA), β-actin (ab115777; Abcam, Cambridge, MA ), PARP1 (9532S; Cell
Signaling technology, Danvers, MA), Phospho RNA polymerase II (S2) (A300-654A;
Bethyl, Montgomery, TX) and Fli-1 (sc-365294; Santa Cruz, Dallas, TX). This step was
followed by incubation with a secondary anti- rabbit IgG HRP-linked antibody (7074S;
Cell Signaling technology, Danvers, MA), and protein bands were visualized with a
Chemidoc MP imager (Bio-Rad, Hercules, CA).
RNA isolation and quantitative real-time polymerase chain reaction analysis
(qRT-PCR).
TC-32, A549, PC3, A673 and TC-32shEWS-FLI1#6 cells were seeded in
6-well plates (VWR, Radnor, PA). Allowed to attach for 24 hours and treated for 6 hours
with the respective compounds dissolved in DMSO (Sigma, St. Louis, MO). Total RNA
was isolated from the cells by using RNeasy mini kit (Qiagen, Hilden, Germany). In each
case, cDNA was generated from 500 ng of RNA by using an iScript™ cDNA Synthesis
Kit (Bio-Rad, Hercules, CA). Five microliters of diluted cDNA (1:40) was mixed with
SYBRGreen (2X), forward (100 nM) and reverse (100 nM) primers for each gene
(CDK12, BRCA2, FANC1 or FANCD2) for a total of 20 µL per reaction. Reactions
were loaded into a 384-well PCR plate (Thermo Fisher Scientific, Waltham, MA) with
an epMotion Editor 4.0 (Eppendorf, Hamburg, Germany) and RT-PCR was performed
on the QuantStudio 7 FLEX Real-Time PCR system (Applied Biosystems, Foster city,
CA). Fold induction values were calculated according to the following equation: fold
change = 2-ΔΔCt, where ΔCt represents the differences in cycle threshold numbers
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between the target gene and reference gene and ΔΔCt represents the relative change in
these differences between the control and treatment groups.
Cell viability and synergy studies
Cells were seeded onto 384-well tissue culture treated (VWR, Radnor,
PA) plates at a density of 25,000 cells/ml. Cells were then allowed to adhere to the plates
for 24 hours, cells in duplicate wells were treated with half-log increments of respective
compounds (0 nM and 3 nM – 10 µM) or a combination of compounds. Following
treatment, cell viability was measured for vehicle control (Day 0) wells. Cell viability
was measured in the remaining wells after 72 hours of incubation with compound or
vehicle control (Day 3). For viability measurements, 0.1 mM resazurin (Sigma, St. Louis,
MO) was added to wells. After 3 hours of incubation at 37°C, fluorescence readings
(Em. 560 nm, Ex. 590 nm) were recorded using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, CA).
Assessment of synergy
The combination index (CI) scores were used to quantitatively assess the
effect of combining olaparib and MTMSA-TRP. CI scores < 0.9, were used to indicate a
synergistic effect of the drug combination and a CI > 1.1 indicated that the combination
was antagonistic. The combination was considered to have an additive effect when
0.9<CI<1.1. The CI scores were computed based on the Chou-Talalay Median Effect
model as implemented in CompuSyn (ComboSyn, Inc., Paramus, NJ). The degree of
interaction between drugs was estimated according to the classification presented by
Chou-Talalay [187]. CI scores for each experiment and cell line are listed in Appendix 2.
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Drug formulation
MTMSA-TRP was formulated in 2.5% Kolliphor (Sigma, St. Louis, MO)
and 97.5% saline (Sigma, St. Louis, MO). Olaparib (LC Laboratories, Woburn, MA) was
dissolved in DMSO (Sigma, St. Louis, MO) (200mg/ml). Olaparib solution was then
mixed dropwise with 10% Hydroxypropyl-β-cyclodextrin (Sigma, St. Louis, MO) in
PBS.
Efficacy of Olaparib and MTMSA-TRP combination
TC-32 cells were grown to sub confluence as indicated in section 4.2.2.
Cells were trypsinized and suspended in 1:1 media (no FBS): Matrigel (Corning,
Corning,NY) on ice and injected subcutaneously into the flank of female athymic nu/nu
mice at densities of 1.0x106 cells per 100 µL. After 10 – 14 days mice with established
tumors larger than 5 mm in one dimension and at least 35mm3, were treated for five
days. Mice were weighed daily prior to being dosed intraperitoneal (IP) with 100 mg/kg
olaparib twice daily. MTMSA-TRP was administered once daily, between Olaparib
dosing as an intravenous (IV) bolus dose of either 1.83 mg/kg (1/3 MTMSA-TRP MTD)
or 1.1 mg/kg MTMSA-TRP (1/5 MTMSA-TRP MTD). Table 4.1 shows the treatment
groups of this study. Tumor measurements were recorded every other day during dosing
and twice a week thereafter.
Table 4.1. Treatment groups (8 mice/group) for combination xenograft study.
Treatment
Group
1
2
3
4
5

Vehicle

Olaparib
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MTMSA-TRP
(1/3 MTD)

MTMSA-TRP
(1/5 MTD)

Statistical Analyses
Differences in tumor volume were estimated with ANOVA repeated
measures. Survival was assessed using the Log Rank test with Mantel-Cox procedure.
All comparisons were relative to the vehicle. Results were statistically significant when p
<0.05.

Results and discussion
MTM and MTMSA analogues physically interact with total RNAPII
RNAPII regulates transcription in the cell. Previous reports demonstrate
that MTM inhibits transcription [188]. Here we sought to determine target engagement
between MTM and analogues and RNAPII. CETSA assays were also used to determine
if there is a physical interaction with MTM analogues and total RNAPII. Upon
completion of the experiment relative band intensities were measured, normalized to the
lowest temperature, and plotted against the temperature to generate a Tagg (the
temperature at which a majority of the unliganded protein has denatured and aggregated)
for each analogue. In these studies, results are somewhat inconclusive.
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Figure 4.1. CETSA demonstrating MTM analogues interact with RNAPII. TC-32 cells treated with DMSO (0.01%), MTM, MTMSATRP, MTMSA-TRP-TRP, MTMox20 or MTMox24 (10 µM). Total RNAPII (~225 kDa) was probed using traditional western blotting
methods. This is a representative experiment from 3 biological replicates.

MTM analogues down regulate RNAPII pSer2 protein expression in an EWSFLI1 dependent manner
Results from TR-FRET studies and CETSA studies suggested a physical
interaction in the form of stabilization between MTM analogues and EWS-ETS
transcription factors. Because of this interaction we sought to identify how MTM
analogues affect transcription. Protein expression of RNAPII pSer2 was assessed in TC32 and PC3 cell lines. Here we observed a concentration-dependent, EWS-FLI1
dependent decrease in pSer2 expression (Figure 4.2 (western blot) and Figure 4.3 (semiquantitative assessment of bands in Figure 4.2). MTM and analogues also influenced
expression of pSer2, pSer5 and pSer7. Results for these studies can be found in
APPENDIX 3.
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Figure 4.2. Protein expression of pSer2 (RNAPII ~225kDa) in TC-32 (A) and PC3 (B) cells is down regulated after treatment with
MTM, MTMSA-TRP and MTMSA-TRP-TRP. THZ1, a CDK12 inhibitor was used as a positive control. Total RNAPII expression was
monitored to demonstrate that analogues do not decrease total transcription.
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Figure 4.3 Quantification of western blot bands. TC-32 (A) and PC3 (B) cells underwent
12-hour treatments with MTM, MTMSA-TRP and MTMSA-TRP-TRP. After SDS PAGE
and western blot, bands were quantified and normalized to relative intensities of total
RNAPII. Error bars represent (S.E.M.) of 3 biological replicates.
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MTM analogues down regulate mRNA expression of CDK12 in a concentration
dependent and EWS-FLI1 dependent manner
CDK12 is important for the regulation of transcription elongation,
splicing, and cleavage/polyadenylation. Expression studies have demonstrated that
CDK12 depletion promotes down regulation of several genes involved in DNA damage
repair (DDR). Here we examined the effect MTM and analogues on mRNA expression
of several DDR genes. Cells were treated with THZ1, a CDK12 inhibitor as a positive
control and demonstrate that CDK12, BRCA1, FANC1 and FANCD2 mRNA expression
is down regulated after MTM and analogue treatment. Expression of mRNA by qRTPCR was evaluated in PC3, TC-32, A673 (EWS-FLI1) and TC-32 shEWS-FLI1#6
(silenced EWS-FLI1) cells (Figure 4.4 - Figure 4.11). Expression patterns demonstrate
an EWS-FLI1, concentration dependent down regulation of DNA damage repair protein
mRNA expression. In contrast, treatment with MTM and analogues has no effect on the
gene expression of these DDR genes in PC3 and EWS-FLI1 silenced TC-32 cells.
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Figure 4.4. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in PC3
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.5. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in PC3
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.6. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in TC-32
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.7. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in TC-32
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.8. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in PC3
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.9. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in PC3
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.10. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in TC-32
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.
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Figure 4.11. mRNA expression of DNA damage repair proteins CDK12 (A), BRCA1 (B), FANC1 (C) and FANCD2 (D) in TC-32
cells after 6-hour treatments with MTM and select MTMSA analogues. These data represent the average of 3 biological replicates.
Each experiment was conducted as 3 of technical replicates.

MTM analogues bind DNA and induce dsDNA damage and apoptosis in EWSFLI1 expressing cells
The CTD of RNAPII is very important in the regulation many cellular
processes centered around transcription. Specifically, the second serine residue is
phosphorylated through transcription by CDK12 which is responsible for regulating
expression of DNA damage repair proteins. Protein expression studies revealed that pSer2 expression was down regulated in the presence of MTM analogues which led to the
question of how this affects the integrity of the DNA. Here it is demonstrated that MTM
analogues induce expression of γH2AX, a biomarker for dsDNA breaks, in a
concentration dependent and in an EWS-FLI1 dependent manner. Figure 4.12
demonstrates that TC-32 cells are sensitive to DNA damaging agents and this is also true
for MTM analogues, suggesting that MTM analogues can be classified as DNA
damaging agents. In contrast Figure 4.14 demonstrates that the effect is specific to cell
lines expressing EWS-FLI1, here PC3 cells, a prostate cancer cell line, there is very little
expression of γH2AX after treatment with MTM and analogues. In Figure 4.13 protein
expression of cleaved PARP1 is evaluated demonstrating that MTM analogues also
induce apoptosis in EWS-FLI1 expressing cells.
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Figure 4.12. Protein expression of γH2AX and β-actin (loading control) in TC-32 cells after 12-hour treatment with MTM and analogues
were compared to solvent control (SC 0.01% DMSO)
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Figure 4.13. Protein expression of cleaved-PARP1 in TC-32 cells after 12-hour treatment with MTM analogues were compared to
solvent control (SC 0.01% DMSO)

Figure 4.14. Protein expression of γH2AX and β-actin (loading control) in PC3 cells after 12-hour treatment with MTM and analogues
were compared to solvent control (SC 0.01% DMSO)
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MTM analogues synergize with olaparib in an EWS-FLI1dependent manner
Cell viability studies were conducted to demonstrate synthetic lethality
conferred on cell lines specifically expressing EWS-FLI1. TC-32 (EWS-FLI1) and PC3
cells (prostate carcinoma) were treated with the indicated drug combinations in Figure
4.15. Most of the drug combinations were calculated to be synergistic in TC32 cells as
opposed to the PC3 cell line, which demonstrated more antagonistic drug combinations.
Cell lines expressing the TRIP-Z silencing vector, A673 and TC-32 shEWS-FLI1#6 were
also subjected to cell viability studies to demonstrate EWS-FLI1 dependent synergy in
Figure 4.16. The ES2 cell line expresses EWS-FLI1 but was shown to be more resistant
to treatment with MTM analogues [1]. In Figure 4.17 the ES2 cell line was subjected to
cell viability studies to demonstrate synergy in a more resistant cell line.
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Figure 4.15. Screening for synergistic drug interactions of olaparib and MTM analogues.
TC-32 and PC3 cells were treated for 72 hours with indicated concentrations of MTM,
MTMSA-PHE, MTMSA-TRP, MTMSA-PHE-TRP and MTMSA-TRP-TRP in
combination with olaparib. Cell viability was assessed by resazurin. Synergistic, additive,
or antagonistic drug interactions were calculated by combination index (CI). The average
CI value of three experiments was then used to generate a heat map of drug interactions
according to the sub classification where CI < 0.9 is synergistic (green), 0.9 < CI < 1.10 is
additive (yellow) and CI > 1.10 are antagonistic (red).
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Figure 4.16. Screening for synergistic drug interactions of olaparib and MTM analogues.
Cell lines A673 and TC32shEWS-FLI1#6 (treated with doxycycline) cell lines were treated
for 72 hours with indicated concentrations of MTM, MTMSA-PHE, MTMSA-TRP,
MTMSA-PHE-TRP and MTMSA-TRP-TRP in combination with olaparib. Cell viability
was assessed by resazurin. Synergistic, additive, or antagonistic drug interactions were
calculated by combination index (CI). The average CI value of three experiments was then
used to generate a heat map of drug interactions according to the sub classification where
CI < 0.9 is synergistic (green), 0.9 < CI < 1.10 is additive (yellow) and CI > 1.10 are
antagonistic (red).
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Figure 4.17. Screening for synergistic drug interactions of olaparib and MTM analogues.
The ES-2 cell line was treated for 72 hours with indicated concentrations of MTM,
MTMSA-PHE, MTMSA-TRP, and MTMSA-TRP-TRP in combination with olaparib. Cell
viability was assessed by resazurin. Synergistic, additive, or antagonistic drug interactions
were calculated by combination index (CI). The average CI value of three experiments was
then used to generate a heat map of drug interactions according to the sub classification
where CI < 0.9 is synergistic (green), 0.9 < CI < 1.10 is additive (yellow) and CI > 1.10
are antagonistic (red).
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Olaparib sensitizes Ewing sarcoma tumors to treatment with MTMSA-TRP
Compared to MTM, MTMSA-TRP had excellent selective cytotoxicity
and displacement against ETS fusion dependent cell lines in vitro (Table 3.1) [1].
Additionally, it’s plasma exposure (AUC∞/D) was 45 fold compared to MTM in
pharmacokinetic studies [1]. The single dose MTD of MTMSA-TRP in mice was 5.5
mg/kg and at this dose there was a marked reduction in tumor size in xenograft studies.
In section in vitro combination studies revealed synergistic combinations that were
EWS-FLI1 dependent (Figure 4.15 and Figure 4.16). Here we sought to investigate the
possibility of MTMSA-TRP being combined with the PARP1 inhibitor olaparib in vivo.
Olaparib was administered by intraperitoneal (IP) injection twice daily for
5 days at 100 mg/kg per injection for 10 total injections. MTMSA-TRP treatment was
administered by intravenous bolus once daily for 5 days at 1.83 mg/kg (1/3 MTD) for 5
total injections. Efficacy was compared to treatment with MTMSA-TRP (1.83 mg/kg),
MTMSA-TRP (1.1 mg/kg), olaparib (100 mg/kg) and treatment with vehicle on the same
dosing schedule. MTMSA-TRP significantly inhibited TC-32 tumor growth in female
NU/NU mice. Tumor volumes of MTMSA-TRP only (1/3 MTD), MTMSA-TRP (1/5
MTD) + olaparib, and MTMSA-TRP (1/3 MTD) + olaparib evaluated 16 days after
tumor implantation were markedly inhibited, this difference was statistically significant
as compared to vehicle treated animals (p=0.0004, p = 0.0004, p = 0.0005 respectively
one-way ANOVA multiple comparisons test). In comparison, MTMSA-TRP (1/3 MTD)
+ olaparib treatment was nominally more effective than MTMSA-TRP only treatment
but was not statistically significant (p>0.9999). Tumor volumes of MTMSA-TRP (1/5
MTD) + olaparib, and MTMSA-TRP (1/3 MTD) + olaparib were also evaluated 37 days
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after tumor implantation and compared to MTMSA-TRP only (1/3 MTD) and
differences appeared markedly different but was not statistically significant as compared
to MTMSA-TRP only (1/3 MTD) treated animals (p=0.1500, p=0.4207 respectively oneway ANOVA multiple comparisons test). Tumor volumes on day 44 however showed
statistically significant differences between MTMSA-TRP (1/3 MTD) only and
MTMSA-TRP (1/3 MTD) + olaparib (p = 0.0004). However, in comparison with
MTMSA-TRP (1/5 MTD) + olaparib on day 44 results were not statistically significant
(p = 0.8072). Consistent with these observations, both MTMSA-TRP (1/5 MTD),
MTMSA-TRP (1/3 MTD) + olaparib and MTMSA-TRP (1/5 MTD) + olaparib
treatments benefited survival (Log Rank (Mantel-Cox) single comparison tests).
In addition to the TC-32 cell line of Ewing sarcoma, in future studies we
plan to test the ES-2 Ewing sarcoma cell line. ES-2 cells have shown to be more resistant
to treatment with MTM analogues despite their expression of EWS-FLI1. Preliminary
combination studies with olaparib demonstrate synergistic combinations, and future
xenograft studies will be completed using this cell line.

124

Tumor Volume (mm3 )

A 1500

Control
Olaparib

1200

1/3 TRP

900

Olaparib+1/5 TRP

600

Olaparib+1/3 TRP

300
0
0

10

20

30

40

50

60

Time (days)

Probability of Survival

B

100
75
50
25
0
0

10 20 30 40 50 60 70 80 90 100

Time (Days)

Figure 4.18. Efficacy study in TC-32 cells (EWS-FLI1) subcutaneously implanted in
female NU/NU mice. Average tumor volume (A) and survival (B) of mice (n=8/group)
treated with vehicle (black), olaparib (pink), MTMSA-TRP (1/3 MTD) (green),
MTMSA-TRP (1/3 MTD) +olaparib (purple) and MTMSA-TRP (1/5 MTD) (light
purple), at respective doses. Treatments were administered every day for 5 days for 5
injections by intravenous bolus doses and 10 total olaparib injections (small dashes).
Significance (p value) of survival was determined using Log Rank (Mantel-Cox), single
comparison to vehicle statistical test.
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Conclusion
The main objective of the previous studies was to elucidate synergy
between MTM or analogue and olaparib. These experiments were based on evidence that
MTM analogues induce DNA damage specifically in EWS-FLI1 expressing cell lines. It
was also based on previous reports that demonstrated that cell lines expressing EWSFLI1 are extremely sensitive to DNA damaging agents and that EWS-FLI1 is a
biomarker for PARP1 inhibition.
Based on the previous studies we hypothesized that MTM and analogues
affect overall transcription. TC-32 and PC3 cells were treated with MTM and analogues
and expression of p-Ser2 (RNAPII CTD) was probed. Here we observed a concentration
and EWS-FLI1 dependent decrease in expression of this peptide. Previous reports have
indicated that Ser2 is phosphorylated by CDK12 which is important in DDR.
Specifically, CDK12 is responsible for recruiting DDR genes (BRCA1, FANC1 and
FANCD2) involved in homologous recombination. Based on this knowledge we then
measured mRNA expression of CDK12 and HR DDR genes BRCA1, FANC1 and
FANCD2 [85, 172-174]. Here we also observed a concentration, EWS-FLI1 dependent in
expression of these genes. We then sought to measure DNA damage in TC-32 and PC3
cells by probing for γ-H2AX, a marker for double stranded DNA breaks. Here we again
observed a concentration, EWS-FLI1 dependent decrease in expression of this peptide.
These results ultimately reveal that MTM analogues specifically target EWS-FLI1 and
physically interact with the transcription factor.
Here we also carried out combination experiments where TC-32 and PC3
cells were treated with combinations of MTM, MTMSA-TRP, MTMSA-PHE, MTMSAPHE-TRP or MTMSA-TRP-TRP and olaparib. In TC-32 cells nearly all the combination
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treatments were synergistic and a few, especially in the MTM treated combinations, were
nearly additive. In contrast PC3 cells showed combinations to be mostly antagonistic.
This result led us to investigate the combination of MTMSA-TRP and olaparib in vivo.
MTMSA-TRP was chosen because it has shown to be one the most promising analogues
in vitro and this has translated in vivo. Preliminary results showed a complete regression
of Ewing sarcoma tumors in athymic nu/nu mice after treatment with MTMSA-TRP (5.5
mg/kg) at the maximum tolerated dose (MTD). This experiment was also conducted at
1/3 of the MTD (1.83 mg/kg) and there was a complete regression, but tumors began to
grow back after 30 days. Here we dosed athymic nu/nu mice with MTMSA-TRP (1/3
MTD) and pre-treated with olaparib (100 mg/kg). This study demonstrated that olaparib
sensitizes tumors to treatment with MTMSA-TRP. It also demonstrated that at lower
doses of MTMSA-TRP (1/5 MTD), tumor regression is not as affected by the addition of
olaparib.
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CHAPTER 5. CONCLUSIONS
This work sought to evaluate molecular differences in the mechanism of
action of MTM and its analogues with semi synthetic modifications of its C3 side chain.
Specifically, it has been of interest to target and selectively inhibit oncogenic ETS
transcription factors like EWS-FLI1 while bypassing the ubiquitously expressed Sp1
transcription factor. In efforts to reduce toxicities associated with MTM two semisynthetic efforts were carried out developing two classes of MTM analogues, MTMSA, a
mutant MTM product bioengineered to produce novel MTMSA analogues and MTMox,
the formation of an oxime linker on MTM side chain to directly add modifications.
Based on studies evaluating the pKa of the new analogues, the data
demonstrate that the shift in pKa reduces interaction with OATP transporters and leads to
a reduction in uptake into the liver. Preliminary pharmacokinetic evidence demonstrated
that MTM is cleared from systemic circulation rather rapidly. In comparing
pharmacokinetic results for MTM to a few of its analogues, MTMSA-TRP, MTMSATRP-TRP and MTMox24 we observed that these analogues displayed an extended plasma
half-life compared to that of MTM. Based on these results we sought to experimentally
estimate the pKa of each analogue. As substitutions were added to the MTM C3 side
chain, we observed an increase in pKa. These differences in pKa were a result of
modifications to the C3 side chain blocking buffer access to the 3-ring aromatic core, the
ionizable portion of the compound. Analogues such as MTMox24 with a pKa of 6.8 and
MTMSA-TRP-TRP with a pKa of 7.1 have a di-peptide TRP at their C3 side chain, these
hydrophobic additions inhibit ionization at the aromatic core. Once buffer is added and
fluorescence is read these bulky side groups shield the fluorescent core of the molecule
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from ionization, shifting the pKa. This result served as initial evidence for its uptake into
OATP transporters.
Based on pKa estimations, in vitro studies were conducted to investigate
intracellular uptake of MTM and MTMSA-TRP-TRP. However due to low LOQ these
studies did not provide adequate data. Alternatively, we investigated MTM and
analogues as substrates for OATP by developing a competitive inhibition assay. The
competitive inhibition assay demonstrated an ionization dependent competitiveness with
the OATP substrate 8-FcA. Overall, these experiments demonstrated that in cells
expressing OATP MTM analogues that are more ionized at physiological pH have more
of an affinity for OATP uptake. This is possibly why MTM has been shown to cause so
much hepatotoxicity compared to other analogues.
Limitations to this study were our inability to measure intracellular
concentrations of MTM and analogues. Also, we lacked an ideal mouse model to
complete in vivo studies that completely blocked uptake of OATP substrates.
Additionally, we were unable to definitively identify the relative differences among
analogues in terms of being substrates for OATP.
In completing these studies, we learned the importance OATP transporters
play in the ADME (absorption, distribution, metabolism, elimination) of MTM and its
analogues. We also learned that MTM analogues interaction with OATP transporters is
highly dependent on their ionization constant. These findings give implications for future
development of MTM analogues keeping in mind the toxicities associated with the rapid
elimination of these compounds via the liver. Future studies should include cell culture
studies using primary hepatocytes to measure influx of MTM analogues, method
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development for the measurement of intracellular concentrations, and animal studies
measuring biodistribution of MTM and analogues focusing on OATP transporters that
may be compensating for the knock down of OATP1B1 and OATP1B3. Understanding
these characteristics of MTM analogues will help to develop a safer more efficacious
MTM analogue for the treatment of Ewing sarcoma.
In this work we also sought to identify if there is a physical interaction
between MTM analogues and EWS-FLI1 or EWS-ERG transcription factors. Here we
developed TR-FRET and CETSA assays that demonstrated MTM analogues with TRP
on its C3 side chain displace and stabilize ETS transcription factors. This is important
because MTM binding to DNA and hindering replication fork mobility can cause
stabilization resulting in downstream dsDNA damage. CETSA assays probing for
stabilization of Sp1 however, showed minimal differences between DMSO treated
samples and analogue treated samples. These data suggest that analogues are not
physically interacting with Sp1, it may also mean that Sp1 is bound to DNA and it’s not
dissociating under CETSA conditions.
In completing these studies, we defined specific MTM analogues that
bind and displace ETS transcription factor binding. Moreover, we identified MTM
analogues that physically interact with ETS transcription factors. These studies also
implicated MTM analogue specific selectivity for ETS and Sp1 binding sites. We
successfully demonstrated MTM and analogue targeted ETS promoter site binding, but
there is still however a concern that these analogues interfere with Sp1 binding.
Although, the results show that MTM analogues more potently target ETS binding than
Sp1 we do not know to what degree Sp1 displacement will be toxic to normal cells.
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We demonstrated that not only do the analogues cause
displacement/stabilization in comparison to MTM, but we also demonstrated, through
CETSA, that there is evidence for stabilization of RNAPII. MTM analogues were also
shown to impart a downstream effect on RNAPII CTD phosphorylation at Ser2. Ser2 on
the RNAPII CTD is phosphorylated by CDK12, recruiting DNA repair enzymes
(BRCA1, FANC1 and FAND2) to lesions on DNA this led us to investigate the effect of
MTM analogues on mRNA expression in an Ewing vs. non-Ewing cell line. Here we
demonstrated that MTM analogues not only specifically down regulate expression of
these enzymes in EWS-FLI1 expressing cells, but they also induce dsDNA breaks in an
EWS-FLI1 and concentration dependent manner. Suggesting that EWS-FLI1 plays an
integral part in rendering damage on cellular DNA. This finding led us to investigate
deeper the relationship between MTM analogues, DNA damage and EWS-FLI1.
Previous reports detail that EWS-FLI1 is a biomarker for PARP1 inhibition. Cell
viability studies were conducted after combining treatments of MTM analogue and
olaparib and we demonstrated synergistic combinations of MTM analogues and olaparib.
In vivo studies demonstrated that olaparib pre - treated tumors can sustain regression for
a longer period as well. In these studies, we gained an understanding of how MTM
analogues affect transcription in EWS-FLI1 expressing cells. CDK12 is vastly important
for normal cells to continue to grow and multiply but here we identified it is vastly
important for Ewing sarcoma cells to thrive and repair themselves after a DNA damaging
event. Limitations to this work were that we did not prove synergy in the combination
study in vivo and more studies should be done to analyze tumors and biodistribution of
the analogues after the combination treatment. Despite these limitations this work in all
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has in part defined MTM and analogue differences in relation to their mechanism on
EWS-FLI1. It has also shown that MTMSA-TRP in combination with olaparib has
potential for clinical success in treating tumors possessing the EWS-FLI1 translocation.
Future work should focus on understanding the molecular mechanism by
which MTM and analogues affect CDK12. MTM and analogues have been shown to
directly bind to DNA but is it possible that these analogues could also be physically
interacting with enzymes that are implicated in DDR? In vitro and in vivo synergistic
studies combining olaparib and MTM analogues demonstrated that MTM analogues and
olaparib are a synthetically lethal combination. MTM analogues inducing the expression
of γH2AX and olaparib suppressing the DDR capabilities of PARP1 has allowed for a
decrease in dosing of a potentially harmful chemotherapeutic. This can potentially have
clinical implications with MTMSA-TRP (at a low dose) in combination with olaparib
being used treat Ewing sarcoma. Allowing for less adverse effects associated with MTM
SA-TRP treatment and olaparib being clinically proven to be safe for patients at higher
doses, the combination of these two drugs could successfully treat Ewing sarcoma
patients.
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APPENDICES
APPENDIX 1: Plasmid Sequences
pOTB7 sequence obtained from Harvard Medical school (Sp1 insert in green):

Plasmid map of pOTB7-Sp1
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CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAA
CCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTT
TCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTA
GTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACAT
ACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGT
CGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTA
CACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCC
GAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGA
GAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTG
TCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGG
GGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGATCACAACAAAAAGCCC
GCTCATTAGGCGGGCTAAATTCTCATGTTTGACAGCTTATCATCGATAAGCTA
GCGGCCGCTAGCTTTAATGAGTTATCGAGATTTTCAGGAGCTAAGGAAGCTA
AAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCA
TCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACC
AGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTAAAGAAAAATAA
GCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTC
ATCCGGAGTTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAG
TGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGC
TCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAA
GATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCCTAAAGGGTTTATTGA
GAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTT
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AAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAAT
ATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCA
TGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGT
ACTGCGATGAGTGGCAGGGCGGGGCGTAATTGGTACGTCGACGTTAGAACGC
GGCTACAATTAATACATAACCTTATGTATCATACACATACGATTTAGGTGACA
CTATAGAACTCGAAGGATCCACAAGTTTGTACAAAAAAGCAGGCTTGTAAAA
CGACGGCCAGTAACTATAACGGTCCTAAGGTAGCGAGGCCTGGGTGGCGAAT
TCGGCACGAGGGGTCCGGGTTCGCTTGCCTCGTCAGCGTCCGCGTTTTTCCCG
GCCCCCCCCAACCCCCCCGGACAGGACCCCCTTGAGCTTGTCCCTCAGCTGCC
ACCATGAGCGACCAAGATCACTCCATGGATGAAATGACAGCTGTGGTGAAAA
TTGAAAAAGGAGTTGGTGGCAATAATGGGGGCAATGGTAATGGTGGTGGTGC
CTTTTCACAGGCTCGAAGTAGCAGCACAGGCAGTAGCAGCAGCACTGGAGGA
GGAGGGCAGGAGTCCCAGCCATCCCCTTTGGCTCTGCTGGCAGCAACTTGCA
GCAGAATTGAGTCACCCAATGAGAACAGCAACAACTCCCAGGGCCCGAGTC
AGTCAGGGGGAACAGGTGAGCTTGACCTCACAGCCACACAACTTTCACAGGG
TGCCAATGGCTGGCAGATCATCTCTTCCTCCTCTGGGGCTACCCCTACCTCAA
AGGAACAGAGTGGCAGCAGTACCAATGGCAGCAATGGCAGTGAGTCTTCCA
AGAATCGCACAGTCTCTGGTGGGCAGTATGTTGTGGCTGCCGCTCCCAACTTA
CAGAACCAGCAAGTTCTGACAGGACTACCTGGAGTGATGCCTAATATTCAGT
ATCAAGTAATCCCACAGTTCCAGACCGTTGATGGGCAACAGCTGCAGTTTGC
TGCCACTGGGGCCCAAGTGCAGCAGGATGGTTCTGGTCAAATACAGATCATA
CCAGGTGCAAACCAACAGATTATCACAAATCGAGGAAGTGGAGGCAACATC
ATTGCTGCTATGCCAAACCTACTCCAGCAGGCTGTCCCCCTCCAAGGCCTGGC

135

TAATAATGTACTCTCAGGACAGACTCAGTATGTGACCAATGTACCAGTGGCC
CTGAATGGGAACATCACCTTGCTACCTGTCAACAGCGTTTCTGCAGCTACCTT
GACTCCCAGCTCTCAGGCAGTCACGATCAGCAGCTCTGGGTCCCAGGAGAGT
GGCTCACAGCCTGTCACCTCAGGGACTACCATCAGTTCTGCCAGCTTGGTATC
ATCACAAGCCAGTTCCAGCTCCTTTTTCACCAATGCCAATAGCTACTCAACTA
CTACTACCACCAGCAACATGGGAATTATGAACTTTACTACCAGTGGATCATC
AGGGACCAACTCTCAAGGCCAGACACCCCAGAGGGTCAGTGGGCTACAGGG
GTCTGATGCTCTGAACATCCAGCAAAACCAGACATCTGGAGGCTCATTGCAA
GCAGGCCAGCAAAAAGAAGGAGAGCAAAACCAGCAGACACAGCAGCAACA
AATTCTTATCCAGCCTCAGCTAGTTCAAGGGGGACAGGCCCTCCAGGCCCTC
CAAGCAGCACCATTGTCAGGGCAGACCTTTACAACTCAAGCCATCTCCCAGG
AAACCCTCCAGAACCTCCAGCTTCAGGCTGTTCCAAACTCTGGTCCCATCATC
ATCCGGACACCAACAGTGGGGCCCAATGGACAGGTCAGTTGGCAGACTCTAC
AGCTGCAGAACCTCCAAGTTCAGAACCCACAAGCCCAAACAATCACCTTAGC
CCCAATGCAGGGTGTTTCCTTGGGGCAGACCAGCAGCAGCAACACCACTCTC
ACACCCATTGCCTCAGCTGCTTCCATTCCTGCTGGCACAGTCACTGTGAATGC
TGCTCAACTCTCCTCCATGCCAGGCCTCCAGACCATTAACCTCAGTGCATTGG
GTACTTCAGGAATCCAGGTGCACCCAATTCAAGGCCTGCCGTTGGCTATAGC
AAATGCCCCAGGTGATCATGGAGCTCAGCTTGGTCTCCATGGGGCTGGTGGT
GATGGAATACATGATGACACAGCAGGTGGAGAGGAAGGAGAAAACAGCCCA
GATGCCCAACCCCAAGCCGGTCGGAGGACCCGGCGGGAAGCATGCACCTGC
CCCTACTGTAAAGACAGTGAAGGAAGGGGCTCGGGGGATCCTGGCAAAAAG
AAACAGCATATTTGCCACATCCAAGGCTGTGGGAAAGTGTATGGCAAGACCT

136

CTCACCTGCGGGCACACTTGCGCTGGCATACAGGCGAGAGGCCATTTATGTG
TACCTGGTCATACTGTGGGAAACGCTTCACACGTTCGGATGAGCTACAGAGG
CACAAACGTACACACACAGGTGAGAAGAAATTTGCCTGCCCTGAGTGTCCTA
AGCGCTTCATGAGGAGTGACCACCTGTCAAAACATATCAAGACCCACCAGAA
TAAGAAGGGAGGCCCAGGTGTAGCTCTGAGTGTGGGCACTTTGCCCCTGGAC
AGTGGGGCAGGTTCAGAAGGCAGTGGCACTGCCACTCCTTCAGCCCTTATTA
CCACCAATATGGTAGCCATGGAGGCCATCTGTCCAGAGGGCATTGCCCGTCT
TGCCAACAGTGGCATCAACGTCATGCAGGTGGCAGATCTGCAGTCCATTAAT
ATCAGTGGCAATGGCTTCTGAGATCAGGCACCCGGGGCCAGAGACATATGGG
CCATACCCCTTAACCCCGGGATGCAAGGTAGCATGGGTCCAAGAGACATGGA
AGAGAGAGCCATGAAGCATTAAAATGCATGGTGTTGAGAAGAATCAGGAGA
GGGATACAAGAGAGGAGATGGGGTCCCGGCACCCATCTGTATCATCAGTGCC
TCTTTGAAGGTGGGAAACATTAGTGAAAATTCTGTTGGTGCCACGCTTTGATG
AGCATTTGTTTGACCCCAGTTTCTTCTTACACTTCTTACCCCAGCCTACCCTTC
CTGCATTTCTCTTCTCAGCTCTTCCATGATGGATTCCCCCCCCTTCCTAAAGCC
ATCATGCCTTGATAAATATATATGATCATTGAAATACTTTTTAACAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACTCGAGGCATCTATG
TCGGGTGCGGAGAAAGAGGTAATGAAATGGCACATGGTCATAGCTGTTTCCT
GACCCAGCTTTCTTGTACAAAGTGGTAGATCTGCCGGTCTCCCTATAGTGAGT
CGTATTAATTTCGATAAGCCAGGTTAACCTGCATTAATGAATCGGCTGCAGTA
CCCGGGAATTTAACCCGCCTAATGAGCGGGCTTTTTTTTGTGATCCAAAGGAT
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pET28a sequence commercially available:

Plasmid map of pET28a(+)
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ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAG
GCCCCAAGGGGTTATGCTAGTTATTGCTCAGCGGTGGCAGCAGCCAACTCAG
CTTCCTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGC
TCGAGTGCGGCCGCAAGCTTGTCGACGGAGCTCGAATTCGGATCCGCGACCC
ATTTGCTGTCCACCAGTCATGCTAGCCATATGGCTGCCGCGCGGCACCAGGC
CGCTGCTGTGATGATGATGATGATGGCTGCTGCCCATGGTATATCTCCTTCTT
AAAGTTAAACAAAATTATTTCTAGAGGGGAATTGTTATCCGCTCACAATTCCC
CTATAGTGAGTCGTATTAATTTCGCGGGATCGAGATCTCGATCCTCTACGCCG
GACGCATCGTGGCCGGCATCACCGGCGCCACAGGTGCGGTTGCTGGCGCCTA
TATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATG
AGCGCTTGTTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCCGGGGGACTGT
TGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGC
CTCAACCTACTACTGGGCTGCTTCCTAATGCAGGAGTCGCATAAGGGAGAGC
GTCGAGATCCCGGACACCATCGAATGGCGCAAAACCTTTCGCGGTATGGCAT
GATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAACCAGTAA
CGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGC
GTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTGGAA
GCGGCGATGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGG
CGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCAC
GCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCCGATCAACTGGGTG
CCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAAGC
GGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATC
CGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCC
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GGCGTTATTTCTTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTC
CCATGAAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGGGTCAC
CAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTGCG
TCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCG
GAACGGGAAGGCGACTGGAGTGCCATGTCCGGTTTTCAACAAACCATGCAAA
TGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCAACGATCAGAT
GGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCG
GATATCTCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCC
CGCCGTTAACCACCATCAAACAGGATTTTCGCCTGCTGGGGCAAACCAGCGT
GGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCTG
TTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAA
CCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTT
TCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTAAGTTAGCTC
ACTCATTAGGCACCGGGATCTCGACCGATGCCCTTGAGAGCCTTCAACCCAG
TCAGCTCCTTCCGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACT
GTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCAT
TTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCCTGTCGCTTG
CGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCC
ACCAAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCCCAC
GGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGG
TTGCCTTACTGGTTAGCAGAATGAATCACCGATACGCGAGCGAACGTGAAGC
GACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCG
GTTTCCGTGTTTCGTAAAGTCTGGAAACGCGGAAGTCAGCGCCCTGCACCATT
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ATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGTGGAACACCTAC
ATCTGTATTAACGAAGCGCTGGCATTGACCCTGAGTGATTTTTCTCTGGTCCC
GCCGCATCCATACCGCCAGTTGTTTACCCTCACAACGTTCCAGTAACCGGGCA
TGTTCATCATCAGTAACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATC
ATTACCCCCATGAACAGAAATCCCCCTTACACGGAGGCATCAGTGACCAAAC
AGGAAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAAC
GCTTCTGGAGAAACTCAACGAGCTGGACGCGGATGAACAGGCAGACATCTGT
GAATCGCTTCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTT
CGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACA
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAG
CGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAG
CGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAG
TGCACCATATATGCGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATAC
CGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGT
TCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCC
ACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAA
AAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCC
GCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA
ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGT
GCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCC
TTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGG
TGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCC
GACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGAC
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ACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAG
GTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTAC
ACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGG
AAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGT
GGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCA
CGTTAAGGGATTTTGGTCATGAACAATAAAACTGTCTGCTTACATAAACAGT
AATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGC
CGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGC
GATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCG
ATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGT
TACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCG
ACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGC
GATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGT
GAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCC
TGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGC
AATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCG
TAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAACTTTTGCCA
TTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATT
TTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCG
CAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCT
CCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATAT
GAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAAGAATTAATTC
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ATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTC
CGCGCACATTTCCCCGAAAAGTGCCACCTGAAATTGTAAACGTTAATATTTTG
TTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGC
CGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTG
AGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCA
ACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACC
ATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGG
AACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAAC
GTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCT
GGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAAT
GCGCCGCTACAGGGCGCGTCCCATTCGCCA
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Subcloned pET28a-Sp1(Sp1 insert in red):

Plasmid map of pET28a with full length Sp1 insert.
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ATCCGGATATAGTTCCTCCTTTCAGCAAAAAACCCCTCAAGACCCGTTTAGAG
GCCCCAAGGGGTTATGCTAGTTATTGCTCAGCGGTGGCAGCAGCCAACTCAG
CTTCCTTTCGGGCTTTGTTAGCAGCCGGATCTCAGTGGTGGTGGTGGTGGTGC
TCGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTTAAAAAG
TATTTCAATGATCATATATATTTATCAAGGCATGATGGCTTTAGGAAGGGGGG
GGAATCCATCATGGAAGAGCTGAGAAGAGAAATGCAGGAAGGGTAGGCTGG
GGTAAGAAGTGTAAGAAGAAACTGGGGTCAAACAAATGCTCATCAAAGCGT
GGCACCAACAGAATTTTCACTAATGTTTCCCACCTTCAAAGAGGCACTGATG
ATACAGATGGGTGCCGGGACCCCATCTCCTCTCTTGTATCCCTCTCCTGATTC
TTCTCAACACCATGCATTTTAATGCTTCATGGCTCTCTCTTCCATGTCTCTTGG
ACCCATGCTACCTTGCATCCCGGGGTTAAGGGGTATGGCCCATATGTCTCTGG
CCCCGGGTGCCTGATCTCAGAAGCCATTGCCACTGATATTAATGGACTGCAG
ATCTGCCACCTGCATGACGTTGATGCCACTGTTGGCAAGACGGGCAATGCCC
TCTGGACAGATGGCCTCCATGGCTACCATATTGGTGGTAATAAGGGCTGAAG
GAGTGGCAGTGCCACTGCCTTCTGAACCTGCCCCACTGTCCAGGGGCAAAGT
GCCCACACTCAGAGCTACACCTGGGCCTCCCTTCTTATTCTGGTGGGTCTTGA
TATGTTTTGACAGGTGGTCACTCCTCATGAAGCGCTTAGGACACTCAGGGCA
GGCAAATTTCTTCTCACCTGTGTGTGTACGTTTGTGCCTCTGTAGCTCATCCGA
ACGTGTGAAGCGTTTCCCACAGTATGACCAGGTACACATAAATGGCCTCTCG
CCTGTATGCCAGCGCAAGTGTGCCCGCAGGTGAGAGGTCTTGCCATACACTTT
CCCACAGCCTTGGATGTGGCAAATATGCTGTTTCTTTTTGCCAGGATCCCCCG
AGCCCCTTCCTTCACTGTCTTTACAGTAGGGGCAGGTGCATGCTTCCCGCCGG
GTCCTCCGACCGGCTTGGGGTTGGGCATCTGGGCTGTTTTCTCCTTCCTCTCCA
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CCTGCTGTGTCATCATGTATTCCATCACCACCAGCCCCATGGAGACCAAGCTG
AGCTCCATGATCACCTGGGGCATTTGCTATAGCCAACGGCAGGCCTTGAATT
GGGTGCACCTGGATTCCTGAAGTACCCAATGCACTGAGGTTAATGGTCTGGA
GGCCTGGCATGGAGGAGAGTTGAGCAGCATTCACAGTGACTGTGCCAGCAGG
AATGGAAGCAGCTGAGGCAATGGGTGTGAGAGTGGTGTTGCTGCTGCTGGTC
TGCCCCAAGGAAACACCCTGCATTGGGGCTAAGGTGATTGTTTGGGCTTGTG
GGTTCTGAACTTGGAGGTTCTGCAGCTGTAGAGTCTGCCAACTGACCTGTCCA
TTGGGCCCCACTGTTGGTGTCCGGATGATGATGGGACCAGAGTTTGGAACAG
CCTGAAGCTGGAGGTTCTGGAGGGTTTCCTGGGAGATGGCTTGAGTTGTAAA
GGTCTGCCCTGACAATGGTGCTGCTTGGAGGGCCTGGAGGGCCTGTCCCCCTT
GAACTAGCTGAGGCTGGATAAGAATTTGTTGCTGCTGTGTCTGCTGGTTTTGC
TCTCCTTCTTTTTGCTGGCCTGCTTGCAATGAGCCTCCAGATGTCTGGTTTTGC
TGGATGTTCAGAGCATCAGACCCCTGTAGCCCACTGACCCTCTGGGGTGTCTG
GCCTTGAGAGTTGGTCCCTGATGATCCACTGGTAGTAAAGTTCATAATTCCCA
TGTTGCTGGTGGTAGTAGTAGTTGAGTAGCTATTGGCATTGGTGAAAAAGGA
GCTGGAACTGGCTTGTGATGATACCAAGCTGGCAGAACTGATGGTAGTCCCT
GAGGTGACAGGCTGTGAGCCACTCTCCTGGGACCCAGAGCTGCTGATCGTGA
CTGCCTGAGAGCTGGGAGTCAAGGTAGCTGCAGAAACGCTGTTGACAGGTAG
CAAGGTGATGTTCCCATTCAGGGCCACTGGTACATTGGTCACATACTGAGTCT
GTCCTGAGAGTACATTATTAGCCAGGCCTTGGAGGGGGACAGCCTGCTGGAG
TAGGTTTGGCATAGCAGCAATGATGTTGCCTCCACTTCCTCGATTTGTGATAA
TCTGTTGGTTTGCACCTGGTATGATCTGTATTTGACCAGAACCATCCTGCTGC
ACTTGGGCCCCAGTGGCAGCAAACTGCAGCTGTTGCCCATCAACGGTCTGGA
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ACTGTGGGATTACTTGATACTGAATATTAGGCATCACTCCAGGTAGTCCTGTC
AGAACTTGCTGGTTCTGTAAGTTGGGAGCGGCAGCCACAACATACTGCCCAC
CAGAGACTGTGCGATTCTTGGAAGACTCACTGCCATTGCTGCCATTGGTACTG
CTGCCACTCTGTTCCTTTGAGGTAGGGGTAGCCCCAGAGGAGGAAGAGATGA
TCTGCCAGCCATTGGCACCCTGTGAAAGTTGTGTGGCTGTGAGGTCAAGCTCA
CCTGTTCCCCCTGACTGACTCGGGCCCTGGGAGTTGTTGCTGTTCTCATTGGG
TGACTCAATTCTGCTGCAAGTTGCTGCCAGCAGAGCCAAAGGGGATGGCTGG
GACTCCTGCCCTCCTCCTCCAGTGCTGCTGCTACTGCCTGTGCTGCTACTTCG
AGCCTGTGAAAAGGCACCACCACCATTACCATTGCCCCCATTATTGCCACCA
ACTCCTTTTTCAATTTTCACCACAGCTGTCATTTCATCCATGGAGTGATCTTGG
TCGCTCATGGTGGCAGCTGAGGGACAAGCTCAAGGGGGTCCTGTCCGGGGGG
GTTGGGGGGGGCCGGGAAAAACGCGGACGCTGACGAGGCAAGCGAACCCGG
ACCCCTCGTGCCGAATTCGGATCCGCGACCCATTTGCTGTCCACCAGTCATGC
TAGCCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGATG
ATGGCTGCTGCCCATGGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCT
AGAGGGGAATTGTTATCCGCTCACAATTCCCCTATAGTGAGTCGTATTAATTT
CGCGGGATCGAGATCTCGATCCTCTACGCCGGACGCATCGTGGCCGGCATCA
CCGGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCCGACATCACCGATGG
GGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGGCGTGGGT
ATGGTGGCAGGCCCCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATG
CACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTACTACTGGGCTGC
TTCCTAATGCAGGAGTCGCATAAGGGAGAGCGTCGAGATCCCGGACACCATC
GAATGGCGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTC
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AATTCAGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTA
TGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGCCAGCCACG
TTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATT
ACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGAT
TGGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGG
CGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGT
AGAACGAAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCG
CAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGATGCCA
TTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTG
ACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGACT
GGGCGTGGAGCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCG
GGCCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGCTGGCATAAATA
TCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGT
GCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTC
CCACTGCGATGCTGGTTGCCAACGATCAGATGGCGCTGGGCGCAATGCGCGC
CATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATCTCGGTAGTGGGATAC
GACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAAC
AGGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCT
CAGGGCCAGGCGGTGAAGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAA
GAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGC
CGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAG
TGAGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACCGGGATCT
CGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGC
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GGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAACTC
GTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTTTC
GCTGGAGCGCGACGATGATCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCA
CGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTCGGCGAGA
AGCAGGCCATTATCGCCGGCATGGCGGCCCCACGGGTGCGCATGATCGTGCT
CCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCCTTACTGGTTAGCAG
AATGAATCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGT
CTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCGTAAAGT
CTGGAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCG
CAGGATGCTGCTGGCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCG
CTGGCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCA
GTTGTTTACCCTCACAACGTTCCAGTAACCGGGCATGTTCATCATCAGTAACC
CGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAG
AAATCCCCCTTACACGGAGGCATCAGTGACCAAACAGGAAAAAACCGCCCTT
AACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCA
ACGAGCTGGACGCGGATGAACAGGCAGACATCTGTGAATCGCTTCACGACCA
CGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAA
AACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGG
ATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGT
GTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGGAGTGTATACTGG
CTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATATGCG
GTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCT
TCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC
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GGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGAT
AACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGT
AAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGC
ATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTAT
AAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCG
ACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGC
GCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCT
CCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTT
ATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCA
CTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTG
CTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTA
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGC
AAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCT
TTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTT
GGTCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGT
TATGAGCCATATTCAACGGGAAACGTCTTGCTCTAGGCCGCGATTAAATTCCA
ACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCA
ATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTG
TTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGG
TCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTT
ATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAA
CAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGAT
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GCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCT
TTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAA
CGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTG
AACAAGTCTGGAAAGAAATGCATAAACTTTTGCCATTCTCACCGGATTCAGT
CGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAAT
TAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGA
TCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAAC
GGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTT
CATTTGATGCTCGATGAGTTTTTCTAAGAATTAATTCATGAGCGGATACATAT
TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCG
AAAAGTGCCACCTGAAATTGTAAACGTTAATATTTTGTTAAAATTCGCGTTAA
ATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATC
CCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTT
GGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAA
AAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAG
TTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGC
CCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAA
GGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTC
ACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCG
CGTCCCATTCGCCA
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APPENDIX 2: Sp1 CETSA plots
MTM and analogues do not physically interact with Sp1
CETSA assays were also used to determine physical interaction and target
engagement with MTM analogues and Sp1. Most of the toxicity associated with MTM
treatment is due to its ability to inhibit Sp1. Here, CETSA assays were conducted and
upon completion of the experiment relative band intensities were measured, normalized
to the lowest temperature, and plotted against the temperature to generate a Tagg (the
temperature at which a majority of the unliganded protein has denatured and aggregated)
for each analogue. In these studies, results suggested that drug bound MTM and
analogues do not physically interact with the Sp1 transcription factor. In Error! R
eference source not found. this is shown by the expression of Sp1at higher temperatures
after treatment with DMSO and analogues.
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A2.1 Western blot analysis of CETSA samples. TC-32 cells treated with DMSO (0.01%), MTM, MTMSA-TRP, MTMSA-TRP-TRP,
MTMox20 or MTMox24 (10 µM). Sp1 (~80 kDa) was probed using the western blot methods. This is a representative experiment from
3 biological replicates

Sp1 increased temperature plots
Sp1 CETSA assays provided mostly inconclusive results with regards to
understanding target engagement with MTM and its analogues. Here we extended the
Sp1 CETSA melting curve to try and demonstrate differences between the analogues and
the DMSO treated samples. Upon completion of the experiment relative band intensities
were measured, normalized to the lowest temperature, and plotted against the
temperature. In these studies, it suggested that MTM and analogues do not physically
interact with the Sp1 transcription factor even at extremely high temperatures. In Error! R
eference source not found.Figure 3.7 this is shown by the expression of Sp1 at higher
temperatures after treatment with DMSO and analogues. There is no apparent target
engagement when the result of analogue treated cells is compared with that of DMSO
treated cells. A similar result was observed at lower temperatures hinting that 1) MTM
analogues are not involved in target engagement of Sp1 or 2) MTM analogues and
DMSO bind Sp1 an protect it from thermal degradation at almost boiling temperatures.
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A2.2 Western blot analysis of Sp1 in CETSA samples. TC-32 cells treated with DMSO (0.01%), MTM, MTMSA-TRP, MTMSA-TRPTRP (10 µM). Sp1 (~80 kDa) was probed using traditional western blotting methods. This is a representative experiment from 2
biological replicates.

APPENDIX 3: MTM analogues decrease pSer expression on the RNAPII CTD.
Expression of RNAPII CTD Ser2, Ser5, Ser7 phosphorylation after treatment with TC-32 and DU-145 (prostate) cells
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APPENDIX 4: TC32, PC3, A673, TC32 shEWS-FLI1#6 and ES2 heat maps from synergy
studies
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